


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as Express Airbill No. EV 543598770, in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 8-5-05

Signature: Mary Murphy  
(Mary Murphy)

Docket No.: VASG-P02-003  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Application of:  
Gill et al

Application No.: 09/487023

Group Art Unit: 1635

Filed: January 19, 2000

Examiner: McGarry, S.

For: METHOD AND COMPOSITION FOR  
TREATMENT OF KAPOSI'S SARCOMA

MS After Final  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**DECLARATION UNDER 37 C.F.R. §1.132 of Ruiwen Zhang**

Sir:

DR. Ruiwen Zhang, M.D., Ph.D., D.A.B.T., hereby declares and states as follows:

1. I am Associate Professor of Pharmacology & Toxicology and Scientist of Comprehensive Cancer Center, Center for AIDS Research, Gene Therapy Center, Chemoprevention Center, and Center for Aging. I am also Director of Cancer Pharmacology Laboratory. I have worked on the development of cancer pharmacology and therapeutics for over 20 years. A copy of my CV is enclosed with this Declaration.
2. I have read the Office Action issued by the U.S. Patent and Trademark Office on August 5, 2004 in the above-identified patent application. I have also reviewed the references cited in the Office Action, including Uchida et al., U.S. Patent No. 6,150,092. I understand that the Examiner has rejected the pending claims as obvious in view of Uchida et al. in combination with various other references. From a scientific perspective, I do not believe that the Uchida et al. reference renders the claims of the present application obvious. Had I read the Uchida et al.

reference at the time that the present application was filed, January 19, 2000, I would not have been motivated to generate phosphorothioate (PS) modified forms of the VEGF antisense nucleic acids set forth in Uchida et al. I base this conclusion on reasons set forth below.

3. **Phosphorothioate-modified antisense probes:** First, I note that PS-modified antisense probes are designed for use in *in vivo* or cell-based applications of antisense technology. This is because PS-modified nucleic acids have improved resistance to nucleases found in cells. One would have no reason to make a PS-modified form of an antisense nucleic acid unless one intended to use the antisense construct to affect gene expression in cells. Therefore, a demonstration that an unmodified antisense probe is effective in a cell-free assay would not necessarily provoke one to make and test the PS-modified form in a cell-based assay. This is particularly true where, as with Uchida et al., there is a poor correlation between the results seen in the cell-free and cell-based assays.

4. **Cell-free Assays:** Uchida et al. describe experiments testing antisense probes for their effects on VEGF expression. The majority of the data presented by Uchida et al. were based on cell-free assays employing unmodified DNA antisense probes at a concentration of 0.4 micromolar (see, Tables 1-8 of Uchida et al. and col. 20, line 3). Tables 1 and 2 in particular show that dozens of unmodified antisense probes were effective in decreasing VEGF expression in the cell-free assay. In many instances VEGF expression was decreased by greater than 90%.

5. **Cell-based Assays:** Uchida et al. selected six probes that were highly effective in the cell-free assays and tested PS-modified forms of these probes in a cell-based assay. The effects of these probes on VEGF expression in cells are shown in Table 9. The amount of VEGF expression observed by Uchida et al. in the presence of the PS-modified probes was high, ranging from 54% to 70% of normal (59% to 82% when corrected for the baseline inhibition seen in the controls).

The cell-based assays of Uchida et al. were performed with PS-modified probes at the high concentration of 20 micromolar (Col. 25, line 30). The cell-free assays in Tables 1 and 2 were performed at a concentration of 0.4 micromolar. At a concentration of 20 micromolar, it is often difficult to discern whether an effect on gene expression is due to a specific antisense effect

or a generalized effect on cellular processes. Given the high probe concentration and the small observed effect on VEGF expression in the cell-based assays, I conclude that the antisense probes identified by Uchida et al. are not effective for inhibiting VEGF expression in cells. These data would not have motivated me to modify and test other probes disclosed by Uchida et al. for use in cells.


6. **A Comparison of the Cell-free and Cell-based Assays:** There is a poor correlation between the effectiveness of the unmodified probes in the cell-free assays and the PS-modified probes in the cell-based assays. For example, the unmodified probe A311 (SEQ ID NO:51) inhibited 96% of VEGF expression in the cell-free assay, but the PS-modified form of A311 inhibited only 22% to 28% of VEGF expression in the cell-based assay (at a 50-fold higher concentration). Of six probes that were effective in cell-free assays, all six showed only mild effect on VEGF expression in the cell-based assay. I conclude that there is no reason to expect that any of the probes that Uchida et al. identified in the cell-free assay would be likely to be effective as PS-modified forms.

7. I further state that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: May 27, 2005

Signed: 

Dr. Ruiwen Zhang, M.D., Ph.D., D.A.B.T.



**STANARDIZED CURRICULUM VITAE**  
**UNIVERSITY OF ALABAMA AT BIRMINGHAM**  
**SCHOOL OF MEDICINE FACULTY**

DATE: May 4, 2005

### **PERSONAL INFORMATION**

Name: **Ruiwen Zhang, M.D., Ph.D., D.A.B.T.**

Citizenship: The United States of America

Foreign Language(s): Chinese; Japanese (reading)

Home Address: 4744 Outlook Way  
Marietta, GA 30066

Telephone and FAX: (770) 578-6965

### **RANK/TITLE**

Associate Professor  
**(Professor, Effective October 1, 2005)**

Department: Pharmacology and Toxicology

Division: Clinical Pharmacology

Business Address: The University of Alabama at Birmingham  
Department of Pharmacology and Toxicology  
VH 113, Box 600  
1670 University Blvd.  
Birmingham, AL 35294-0019

Business Telephone: (205) 934-8558

Business FAX: (205) 975-9330

Business E-Mail: [ruiwen.zhang@ccc.uab.edu](mailto:ruiwen.zhang@ccc.uab.edu)

### **PROFESSIONAL CONSULATSHIPS:**

2003-2008 US FDA Consultant, Clinical Chemistry and Clinical Toxicology Devices Panel, Medical Devices Advisory Committee, Center for Devices and Radiological Health, FDA

1996-1999 Senior Advisor to the Director General -- National Institute for the Control of Pharmaceutical and Biological Products, Ministry of Health, P.R. China

## **EDUCATION**

Institution	Degree	Year
Shanghai Medical University (SMU)	<b>M.D. (with highest honor)</b>	1983
Shanghai Medical University (SMU)	<b>Ph.D. (Toxicology and Occupational Epidemiology)</b>	1988

## **BOARD CERTIFICATION**

1999	<b>Diplomate, American Board of Toxicology (D.A.B.T.)</b>
2004	<b>Recertification of D.A.B.T.</b>

## **POSTDOCTORAL TRAINING**

1989-1992	<b>Post-Doctoral Fellow/Clinical Pharmacology Fellow, University of Alabama at Birmingham (UAB).</b>
-----------	--

## **ACADEMIC APPOINTMENTS (in reverse chronological order)**

Year	Rank/Title	Institution
2005-Present	Professor (tenured)	Clinical Pharmacology, Pharmacology and Toxicology, UAB
2002-Present	Scientist	Center for Aging, UAB
2001-Present	Scientist	Gene Therapy Center, UAB
1999-2005	Associate Professor (tenured)	Clinical Pharmacology, Pharmacology and Toxicology, UAB
1999-Present	Director	Cancer Pharmacology Laboratory, CCC, UAB
1999-Present	Scientist	UAB Comprehensive Cancer Center
1999-Present	Scientist	UAB Center for AIDS Research
1998-Present	Member	UAB Chemoprevention Center
1995-Present	Faculty Member	MD/PhD Program, UAB School of Medicine
1992-Present	Graduate Faculty	UAB Graduate School

**Curriculum Vitae****Ruiwen Zhang, M.D., Ph.D., D.A.B.T.**

Page 3

Year	Rank/Title	Institution
1994-1999	Assistant Professor (tenure-track)	Clinical Pharmacology, Pharmacology and Toxicology, UAB
1992-1999	Associate Scientist	UAB Comprehensive Cancer Center
1992-1999	Associate Scientist	UAB Center for AIDS Research
1992-1994	Res. Asst. Professor	Clinical Pharmacology, UAB
1989-1992	Clinical Pharmacology Fellow/ UAB Research Associate	
1988-1991	Assistant Professor	Toxicology and Occupational Medicine, SMU
1983-1988	Research/Teaching Associate	Toxicology and Occupational Medicine, SMU
1981-1983	Intern and Resident	SMU Teaching Hospitals

**AWARDS AND HONORS**

- Distinguished Medical Student (SMU, 1979, 1980, 1981, 1982, 1983)
- Outstanding Student of Shanghai (Shanghai, 1983)
- Rong-Lin Medical Prize (Distinguished Medical Graduate, First Place, the highest honor for MD, SMU, 1983)
- Natural Science Research Grant -- *Toxicology of Formaldehyde* (China, 1986-88)
- Excellent Publications Awards (2) -- *Toxicology of chlordimeform* (China, 1987)
- Excellent Publications Award -- *Toxicology of Formaldehyde* (China, 1990)
- National Research Awards -- *Toxicology and Occupational Health of Formaldehyde* (Ministry of Labor, China, 1992)
- Member, Board of Directors, Association of Retard Citizens of Jefferson Co.(1994-97)
- International Leadership -- American Biographic Institute, 1994
- Board Member, Research -- American Biographic Institute, 1994-
- Senior Advisor to the Director General -- National Institute for the Control of Pharmaceutical and Biological Products, Ministry of Health, P.R. China, 1996-1999
- Adjunct Professor -- National Institute for the Control of Pharmaceutical and Biological Products, 1996-1999
- Visiting Professor -- National Academy of Medical Sciences, Beijing, China (Supported by a grant from China National Science Foundation), 1997-
- Faculty Sponsor for ASCPT Presidential Trainee Award (Dr. Xiao-fei Zeng), 1998
- Visiting Scientist, National Clinical Pharmacology Program, Baylor College of Medicine, Houston, TX, 1999
- Faculty Sponsor for ASCPT Presidential Trainee Award (Dr. Hui Wang), 2000

- Faculty Sponsor for 2000 International Society of Predictive Oncology (ISPO) Travel Award (Dr. Hui Wang), 2000
- Faculty Sponsor for 2000 UAB Medical Student Research Competition and National Competition Travel Award (Gautam Prasad, First Place), 2000
- Faculty Sponsor for 2001 National Medical Student Research Forum (Gautam Prasad, Best paper on Oncology), 2001
- Faculty Sponsor for 2003 Graduate Student Travel Award (Zhuo Zhang), UAB
- Faculty Sponsor for 2004 Outstanding Graduate Student (Zhuo Zhang), UAB
- Faculty Sponsor for 2004 Outstanding International Student (Academic Excellence) (Zhuo Zhang), UAB
- Faculty Sponsor for DoD Prostate Cancer Research Program/Post-Doctoral Fellowship (Zhuo Zhang), UAB (2004-2006)
- Adjunct Professor – Nanjing Medical University, 2005-present

## **PROFESSIONAL SOCIETIES/MEMBERSHIPS**

- American Association for Cancer Research (AACR)
- American Society for Biochemistry and Molecular Biology (ASBMB)
- American Society for Clinical Pharmacology and Therapeutics (ASCPT)
- American Association of Pharmaceutical Scientists (AAPS)
- American College of Toxicology (ACT)
- Fellow, Molecular Medicine Society
- American Society for Microbiology (ASM)
- American Chemical Society (ACS)
- Drug Information Association (DIA)
- American Association for the Advancement of Science (AAAS)
- International Society for Nucleosides, Nucleotides, and Nucleic Acids (IS3NA)
- Society of Chinese Bioscientists in America (SCBA)

## **COUNCILS AND COMMITTEES**

**(Federal/National/International Review Panel/Study Section; Partial List; After 2000)**

2000	Reviewer, DOD Research Programs
2000	Reviewer and Study Section Member, Michigan Life Science Corridor
2002	DOD Breast Cancer Research Program, Panel Member (Molecular Biology and Genetics-4)
2002-date	NIH Study Section ZRG1 SSS-1 10B (Diagnosis and Treatment of Cancer)
2003	DOD Breast Cancer Research Program, Panel Member (Pathobiology 5)
2003	DOD Breast Cancer Research Program, Panel Member (Ad hoc panel-2)
2003	Reviewer, Cancer Research UK
2003-2008	US FDA Consultant, Clinical Chemistry and Clinical Toxicology Devices Panel, Medical Devices Advisory Committee, Center for Devices and Radiological Health, FDA

**Curriculum Vitae****Ruiwen Zhang, M.D., Ph.D., D.A.B.T.****Page 5**

2004 DOD Prostate Cancer Research Program, Panel Member (Cell biology 3)  
2004 DOD Breast Cancer Research Program, Panel Member (Molecular Biology and Genetics-3.)  
2004 DOD Breast Cancer Research Program, Panel Member (Pathobiology 5)  
2004 Reviewer, Florida Department of Health Biomedical Research Program

2004 Study Section, Center for Disease Control and Prevention (CDC) Peer Review (R01 Panel 2)  
2004 Reviewer, US Civilian Research Foundation  
2004-date NIH Study Section BMCT (Basic Mechanisms for Cancer Therapeutics)  
2004 NIOSH Study Section/Big NORA (intramural programs; National Occupational Research Agenda)  
2005 DOD Breast Cancer Research Program (2004-Concept Award)  
2005 DOD Prostate Cancer Research Program, Panel Member (Cell Biology 2)  
2005 DOD Prostate Cancer Research Program, Panel Member (Clinical and Experimental Therapeutics 1)  
2005 Reviewer, James and Esther King Biomedical Research Program, Florida  
2005 NIH/NCI P01 Program Study Section, Radiation Biology  
2005 Reviewer, CDC Foundation Peer Review  
2005 Reviewer, International Science and Technology Center, Science and Technology Center in Ukraine  
2005 Reviewer, Wellcome Trust, UK  
2005 DOD Breast Cancer Research Program, Panel Member (Pathobiology 5)  
2005 DOD Anti-Radiation Drug Development Program, Panel Member  
2005 Reviewer, Catalan Agency for Health Technology Assessment and Research (CAHTA), Cancer Research Program, Spain

**UNIVERSITY COMMITTEES**

1994- Faculty Member, MD/PhD Program, School of Medicine  
1995- Clinical Study Review Committee, Comprehensive Cancer Center  
1996- Cancer Prevention Working Group, Comprehensive Cancer Center  
1996- Lung Cancer Working Group, Comprehensive Cancer Center  
1996- Faculty Member, Clinical Investigators Training Program, School of Medicine  
1997- Brain Tumor Working Group, Comprehensive Cancer Center  
1998- Member, Chemoprevention Center  
1999- Judge, UAB Medical Student Research  
2000- Reviewer, American Cancer Society Institutional Grants  
2000- Reviewer, Junior Faculty Development Grants  
2002-2003 Member, Basic Science Advisory Committee (BSAC), UAB SOM  
2002- Judge, Comprehensive Cancer Center Research Competition.  
2003- Reviewer, American Cancer Society Institutional Grants  
2004- Reviewer, American Cancer Society Institutional Grants  
2005- Reviewer, Junior Faculty Development Grants

**EDITORIAL BOARD MEMBERSHIPS**

2000-date Editorial Advisory Board, *Current Cancer Drug Targets*  
2000 Executive Guest Editor, *Current Cancer Drug Targets*  
2002-date Editorial Advisory Board, *Letters in Drug Design and Discovery*  
2003-date Editorial Advisory Board, *Medicinal Chemistry Reviews -Online*  
2003-date Editorial Advisory Board, *Drug Design Reviews -Online*  
2003-date Editorial Committee for Pharmacology, *Foxwell & Davies*  
2004-date Editorial Board, *Medicinal Chemistry*  
2004-date Associate Editor, *Therapeutics and Clinical Risk Management*  
2004-date Editorial Board, *Current Medicinal Chemistry*  
2004-date Editorial Board, *Journal of Biological Sciences*  
2004-2005 Executive Guest Editor, *Current Cancer Drug Targets*  
2005-date Editorial Board, *Recent Patent Reviews on Anti -Cancer Drug Discovery*  
2005-date Editorial Board, *Current Medicinal Chemistry-Anti-Cancer Agents*

## REVIEWER FOR SCIENTIFIC JOURNALS

*Biochemical Pharmacology*  
*Biological Procedure-online*  
*Bioorganic and Medicinal Chemistry*  
*Cancer*  
*Cancer Epidemiology, Biomarkers and Prevention*  
*Cancer Research*  
*Clinical Cancer Research*  
*Clinical Pharmacology and Therapeutics*  
*Current Pharmaceutical Design*  
*Expert Opinion on Therapeutic Patents*  
*Expert Opinion on Therapeutics*  
*Gynecological Oncology*  
*Hepatology*  
*Journal of Biomolecular Screening*  
*Journal of Clinical Oncology*  
*Journal of Liposome Research*  
*Journal of Pharmaceutical Science*  
*Journal of Pharmacology and Experimental Therapeutics*  
*Molecular Cancer Therapeutics*  
*Molecular Medicine*  
*Neoplasia*  
*Oligonucleotides*  
*Oncogene*  
*Pharmaceutical Development and Technology*  
*Southern Medical Journal*

## MAJOR RESEARCH INTERESTS

- Molecular cancer biology and molecular cancer therapeutics

**Curriculum Vitae****Ruiwen Zhang, M.D., Ph.D., D.A.B.T.****Page 7**

- Molecular, biochemical, and clinical pharmacology and experimental therapeutics
- Gene regulation and silencing
- Biotechnology and biopharmaceuticals

In my laboratory, there are three major research projects: 1) cancer chemotherapeutics; 2) oligonucleotide-based gene expression modulators; and 3) chemopreventive agents.

**1. BIOCHEMICAL AND MOLECULAR PHARMACOLOGY OF ANTI-CANCER THERAPEUTIC AGENTS**

In my laboratory, major efforts in this area are devoted to development of novel small molecular therapeutic agents with defined targets. This project includes the following research areas:

- 1) p53 and MDM2 as a target for cancer therapy;
- 2) Apoptosis as a mechanism for cancer chemotherapy;
- 3) Natural product protein kinase C modulators;
- 4) Natural product topoisomerase I inhibitors;
- 5) Biological and chemical modulators of chemotherapy and radiation therapy.

In addition, as a key investigator of the Cancer Pharmacology Program and Director of Cancer Pharmacology Laboratory in the UAB Comprehensive Cancer Center, I have been intensively involved in clinical trials of anticancer agents including taxol, taxotere, cisplatin, carboplatin, topotecan, 9-AC, gemcitabine, and fluoropyrimidines. We are also one of the major laboratories that have NCI contracts to carry out pre-clinical studies of novel therapeutic agents for cancer and AIDS.

**2. OLIGONUCLEOTIDE THERAPEUTICS (ANTISENSE, RNAi and CpG IMMUNOMODULATORS)**

The use of antisense oligonucleotides targeted to mRNA represents a specific, genetic-based therapy. Antisense oligonucleotides have been suggested to have a potential role in the treatment of cancer, AIDS, hepatitis, and other diseases. My research has been centered around oligonucleotide phosphorothioates and their modified analogs as gene expression modulators in the treatment of HIV/AIDS and cancers. Three oligonucleotides studied in my laboratory have entered clinical trials. We will continue to investigate in the following areas:

- 1) Novel targets for oligonucleotide-based therapy;
- 2) Pharmacokinetics and pharmacodynamics of oligonucleotide therapeutics;
- 3) Mechanisms of action and toxicity;
- 4) Clinical pharmacokinetics and clinical trials;
- 5) Novel means for drug delivery of oligonucleotides; and
- 6) Combination therapy with oligonucleotide therapeutics (chemosensitization and radiosensitization).

Current targets for oligonucleotide-based therapy in my laboratory include HIV, protein kinase A, MDM2, Bcl2, VEGF, TGF- $\beta$ , ICAM-1, survivin, beta-catenin, and p53. More recently, we have been developing immuno-stimulatory oligonucleotides (IMOs) as therapeutic agents for cancer, allergy, and infectious diseases.

**3. PRECLINICAL AND CLINICAL STUDIES OF CANCER CHEMOPREVENTIVE AGENTS**

**Curriculum Vitae**

**Ruiwen Zhang, M.D., Ph.D., D.A.B.T.**

**Page 8**

In my laboratory, major efforts in this area are devoted to pre-clinical and clinical development of chemopreventive agents. This project includes the following research areas:

- 1) In vitro/in vivo correlation of anti-proliferative effects;
- 2) DNA damage and DNA repair;
- 3) In vivo pharmacokinetics and metabolism of novel chemopreventive agents; and
- 4) Apoptosis and oncogene as targets for cancer chemoprevention.

In addition, I have been involved in several clinical trials of cancer prevention in the UAB Comprehensive Cancer Center as a key investigator in clinical pharmacology and toxicology, including sulindac, 9-Cis RA, I-3-C, and celecoxib.

## **TEACHING EXPERIENCE**

1992- Department of Pharmacology and Toxicology, UAB

**Lecture:** *Pharmacogenetics* (Graduate Pharm I)

*Clinical Pharmacology* (Clinical Investigator Training Course)

*Antisense Gene Therapy* (Pathology Graduate 790)

*Cancer Chemotherapy* (Medical/Dental/Optometry)

*Pharmacology*; Graduate Pharmacology PHR705, 706)

*Antifungal Chemotherapy* (Medical/Dental/Optometry)

*Regulatory Toxicology* (Graduate Toxicology TOX 712)

*Good Laboratory Practice* (Graduate Toxicology TOX 712)

*Clinical Toxicology* (Medical Pharmacology)

*Drug Design* (IBS)

**Course Director: *Modern Drug Design and Development* (PHR725)**

Lectures (8) for this Course: *Introduction to Drug Design and Development; Rational Drug Design; In vitro Pharmacology; In vivo Pharmacology and Disease Models; New Approaches to Non-Clinical Biodisposition Studies; GLP/GMP/GCP; Clinical Pharmacology in Drug Development; Contract Research.*

1990- Division of Clinical Pharmacology, UAB

Laboratory/experimental training for graduate and medical students, visiting scholars, and postdoctoral fellows

1985-89 Shanghai Medical University, Schools of Medicine and Public Health

Coursemaster: *Toxicology*

*Occupational Medicine*

Lecture: *Biostatistics*

*Molecular Epidemiology*

## **Mentor/Advisor to Trainees**

### **Post-Doctoral Fellows/Visiting Scientists**

**X. Cheng, BS**

Visiting Scientist (1992-94)

Current Status: Post -Doc, UAB

**H. Zhao, MD** Post-doctoral Fellow (1993-95)  
Current Status: Sr. Scientist, CDC, Atlanta, GA

**X. Zhang, MD, PhD** Post-doctoral Fellow (1994-95)  
Current Status: Research Associate, Mount Sina Medical Center, NY

**Q. Cai, MD, PhD** Post-doctoral Fellow (1995-97)  
Current Status: Assistant Professor, Vanderbilt University

**M. Liao, MD, MSc** Sr. Visiting Scientist (1996)  
Current Status: Professor and Director, Beijing Institute of Pharmacology and Toxicology, China

**Y. Lu, PhD** Sr. Visiting Professor (1996-97)  
Current Status: Professor, Beijing University of Chinese Traditional Medicine, China

**X. Zeng, PhD** Post-doctoral Fellow (1997-98)  
Current Status: Professor and Dean, School of Environment and Life Science, Liaoning University, China; Deputy Director, Department of Public Health, Liaoning Province, China

**P. Oliver, PhD** Post-doctoral Research Associate (1998-2000)  
Current Status: Research Associate, UAB Comprehensive Cancer Center

**H. Wang, MD, PhD** Post-doctoral Fellow/Research Associate (1998-2000)  
Current Status: Assistant Professor, UAB Pharmacology and Toxicology and Comprehensive Cancer Center

**Z. Wang, PhD** Post-doctoral Fellow (2000-2001)  
Current Status: Professor and Dean, School of Natural Sciences, Hebei Agriculture University, China

**S. Wang, MD** Visiting Scholar (2000-2001)  
Current Status: Adjunct Assistant Professor, HHMI/UAB

**P. Liang, MD** Visiting Scholar (2000)  
Current Status: Research Assistant, UAB Center for Aging

**X. Yang, MD** Post-doctoral Fellow (2000-2001)  
Current Status: Professor, Hunan Medical University, China

**Z. Shi, MD** Post-doctoral Fellow (2001-2002)

Current Status: Post-doctoral Fellow, UAB Department of Pathology

**J. Hang, MD** Post-doctoral Fellow (2001)  
Current Status: Sr. Scientist, Peking Union Medical College/Cancer Hospital, Beijing, China

**L. Lin, MSc** Sr. Visiting Scientist (2001-2002)  
Current Status: Sr. Scientist, National Center for Biotechnology and Bioengineering, Beijing, China

**M. Li, MD** Post-doctoral Fellow (2001-2003)  
Current Status: Research Associate, UAB Pharmacology and Toxicology

**Jian-He Wu, MD** Post-doctoral Fellow (2004-)

**W. Wang, MD, MSc** Post-doctoral Fellow/Research Associate (2004-)

**D. Cheng, MD, PhD** Post-doctoral Fellow (2004-)

**Mentor/Committee Member for Graduate/Medical Students**

**G. Prasad, BS** MD- PhD Student (Mentor/Committee Chair, 2000-2004)  
Current Status: M.D. student, UAB Medical School/UCSF Radiation Oncology fellowship

**Z. Zhang, MD** PhD Student, Pharmacology (Mentor/Committee Chair, 2000-2004)  
Current Status: Post-doctoral fellow, UAB Medical School

**V. Schachinger** MS Student, Pharmaceutical Sciences, University of Vienna, Austria (Mentor/Thesis Research, 2002-2003)

**M. Haslinger** MS Student, Pharmaceutical Sciences, University of Vienna, Austria (Mentor/Thesis Research, 2002-2003)

**C. Blauquiceh, BS** PhD Student, Pharmacology (laboratory rotation, 1999; Committee Member, 2002-2005)

**E. Rayburn, BS** Ph.D. Student, Toxicology (Mentor/Committee Chair, 2003-)

**R. H. Graves, BS** Ph.D. Student, Chemistry (Committee Member, 2003-)

**K. A. Delaine, BS** Ph.D. Student, Toxicology (Mentor/Committee Chair, 2003- )

**A. P. Cunningham, BS** M.S. Student, Biology (Committee Member, 2004-)

**X. Zhang, BS** Ph.D. Student, Environmental Health Sciences (Committee Member, 2003-)

**Chanel Douglas, BS** Ph.D. Student, Microbiology (Committee Member, 2005-)

### **Laboratory Training for Graduate/Medical Students**

<b>R. Guttman, BS</b>	Graduate Student, Pharmacology (laboratory rotation, 1991-93)
<b>S. Wiggins, BS</b>	Medical Student (summer research, 1992)
<b>N. Zou, BS, MSc</b>	Graduate Student, Pharmacology (laboratory rotation, 1992)
<b>J. Adams, BS</b>	Medical Student (laboratory rotation, 1994)
<b>T. Williams, BS</b>	Graduate School Summer Internship (1996)
<b>R. Mathew, BS</b>	MPH Graduate Student Research Assistant (1997-1999)
<b>Long P. Le, BS</b>	M.D.- Ph.D. Student (laboratory rotation, 1999-2000)
<b>P. Mookherjee, MS</b>	Graduate Student, Pharmacology (laboratory rotation, 1999)
<b>Y. K. Holt, BS</b>	Graduate Student Summer Internship (1999)
<b>X. Li, BS</b>	Ph.D. Student, Pharmacology (laboratory rotation, 1999)
<b>H. Someya, BS</b>	Ph.D. Student, Pharmacology (laboratory rotation, 2000)
<b>T. D'Alessandro, BS</b>	Ph.D. Student, Pharmacology (laboratory rotation, 2000)
<b>P. Huang, BS</b>	Ph.D. Student, Pharmacology (laboratory rotation, 2002-2003)
<b>M. Sun, BS</b>	Ph.D. Student, IBS (Dissertation Research 2002-2003)
<b>A. Lee, BS</b>	Ph.D. Student, Toxicology (laboratory rotation, 2003)
<b>J. Cramton, BS</b>	Ph.D. Student, Toxicology (laboratory rotation, 2003)
<b>Y. Wang, BS, MS</b>	Ph.D. Student, IBS (laboratory rotation, 2003-2004)
<b>Ashish P. Mogal, BS</b>	Ph.D. Student, IBS (laboratory rotation, 2004)
<b>L. Zhai, BS</b>	Ph.D. Student, IBS (laboratory rotation, 2004-2005)
<b>E. Bashari, BS</b>	Ph.D. Student, IBS (laboratory rotation, 2005)

### **Work-Study Students/Student Assistants**

<b>J. Miller, BS</b>	Work-Study (1989-90)
<b>M. Lusco, BS</b>	Student Assistant (1990-93)
<b>S. Webb, BS</b>	Student Assistant (1992-93)
<b>C. Diasio, BS</b>	Student Assistant (1992-94)
<b>T. Thomas</b>	Work-Study (1992-93)
<b>S. Howland</b>	Work-Study (1992-93)
<b>J. Young</b>	Work-Study (1993-94)
<b>A. Chaves</b>	Work-Study (1993-95)
<b>D. Fletcher, BS</b>	Work-Study (1993-96)
<b>C. Shoemaker</b>	Student Assistant (1994-95)
<b>L. High, BS</b>	Work Study/Student Assistant (1994-97)
<b>S. Avery</b>	Student Assistant (1999)
<b>K. Wang</b>	Student Assistant (2002-2004)
<b>A. Mel</b>	Student Assistant (2002-2003)
<b>B. Ku</b>	Student Assistant (2003)
<b>A. Peyyala, BS</b>	Student Assistant (2003-2004)
<b>K.G.Chaitanya, BS</b>	Student Assistant (2003-2004)

## MAJOR LECTURES AND VISITING PROFESSORSHIPS

2005                   **Shanghai Jiao Tong University:** Drug development: Move forward by failing early, fast, and often. May

2005                   **Nanjing Medical University:** P53-dependent and independent activities of MDM2: Implication in Cancer development, Prevention and Treatment. April

2005                   **2005 Bio-forum, Shanghai:** Accelerating Drug development by novel approaches to pharmacology and toxicology evaluations. April

2005                   **University of California, Los Angles:** Genistein, a soy product, down-regulates the MDM2 oncogene, a previously unrecognized mechanism of action. April

2005                   **Emory University, Winship Cancer Institute:** MDM2; Big brother of p53 and other molecules. April

2005                   **Chinese Academy of Medical Sciences, Cancer Institute:** Novel oligonucleotide therapeutics. March

2005                   **Chinese Academy of Sciences, Shanghai Institute for Nutritional Sciences:** Nutrition-gene interaction. March

2004                   **Nantong University, China:** RNA Silencing—Research and Development. December

2004                   **Chinese Academy of Sciences/Institute of Nutritional Sciences:** Advances in gene silencing. December

2004                   **NIH 7<sup>th</sup> Symposium on Oligonucleotide Therapeutics:** Novel mixed-backbone oligonucleotides in cancer therapy: Monotherapy and combination therapy with chemotherapeutic agents, radiation, and monoclonal antibodies. December

2004                   **Peking Union Medical College and Chinese Academy of Medical Sciences/Cancer Institute/Cancer Hospital:** Advances in experimental therapeutics for human cancers. August

2004                   **UAB Center for Aging and Birmingham/Atlanta VA Geriatric Research, Education and Clinical Center:** Oligonucleotide Therapeutics. February

2003                   **Peking Union Medical College and Chinese Academy of Medical Sciences/Cancer Institute/Cancer Hospital:** cAMP-dependent Protein Kinase (PKA) and Cancer. October

2003           **Dalian University of Technology:** Nucleic Acids Therapeutics. October

2003           **NYU Medical Center:** RNA Silencing: Research and Development. August

2003           **Texas Tech University School of Pharmacy:** Antisense Oligonucleotide Therapeutics: Are We There Yet? March

2003           **UAB Department of Medicine/Division of Hematology and Oncology:** Chemosensitization and Radiosensitization by Antisense Oligonucleotides. March

2002           **NIH 6<sup>th</sup> Symposium on Oligonucleotide Therapeutics:**  
Chemosensitization and Radiosensitization by Antisense Oligonucleotides. December

2002           **NIH:** p53-Dependent and p53-independent activities of MDM2: Antisense approach. September

2001           **NIH:** Antisense Anti-MDM2 Oligonucleotide Therapeutics as a New Approach to Human Cancer Therapy: In vitro and In vitro Studies. April

2001           **UAB Department of Medicine/Division of Hematology and Oncology:**  
Antisense Anticancer Therapeutics. April

2001           **UAB Comprehensive Cancer Center:** Translational Research/Cancer Pharmacology. June

2001           **UAB Gene Therapy Center:** Antisense Gene Therapy, Birmingham, AL, February.

2000           **Chinese Academy of Medical Sciences:** PKA as a Biomarker for Cancer Early Detection. Beijing, China, December.

2000           **The Post-Genome Biotechnology Conference,** Hangzhou, China:  
Antisense Technology, October.

2000           **The fourth Life Sciences Symposium,** Beijing, China: Inhibiting MDM2 expression as a novel approach to human cancer therapy, August.

2000           **The Annual Meeting of Southeastern Pharmacology Society,** Jackson, MS: MDM2 as a novel target for human cancer therapy, August.

2000           **The Fifth World Congress on Advances in Oncology:** Protein Kinase A as a new target for cancer therapy, October.

1999                   **Baylor College of Medicine:** Antisense Oligonucleotide Therapeutics: Preclinical and Clinical Pharmacology, April.

1999                   **University of Mississippi:** Antisense Technology: Rationale, Design, and Evaluation. March.

1999                   **Brown University:** Antisense Gene Therapy, January.

1998                   **The Annual Meeting of Southeastern Pharmacology Society:** Oligonucleotide Therapeutics; Preclinical and Clinical Pharmacology. Sept.

1998                   **The Third World Congress on Advances in Oncology:** MDM2 as a new target for cancer therapy, Greece, October.

1998                   **The 6th Pacific Rim Biotechnology Conference and Bioexpo 98:** Antisense Oligonucleotide Therapeutics: Promises and Pitfalls, June.

1997                   **Chinese Academy of Medical Sciences:** Visiting Professor Lecture-- Pharmacogenetics: Principles and Applications, Beijing, China, October

1997                   **Shanghai Medical University:** Principles and Practice of Modern Drug Development, Shanghai, China, October.

1997                   **The First International Symposium on Gene Therapy:** Antisense Oligonucleotides as Gene Expression Modulators, Beijing, China, July.

1997                   **Chinese Academy of Medical Sciences:** Antisense Oligonucleotides as Gene Expression Modulators: New Generation of Therapeutics? Beijing, China, July.

1997                   **NIH:** Preclinical and Clinical Pharmacology of Oligonucleotide Therapeutics. NIH, Bethesda, MD, Jan.

1996                   **UAB Comprehensive Cancer Center:** In Vitro and in Vivo Anti-tumor Activity of Antisense Oligonucleotides Targeted at Protein Kinase A. Oct.

1996                   **Sino-US Workshop:** Organizing Committee Member and Invited Speaker; A 3-day workshop, **Advances in pharmaceuticals: Academic, industrial, and regulatory aspects**, Beijing, China, July 7-9. Lectures included:  
1) New Drug Development in USA;  
2) New Drug approval: Preclinical Pharmacology and Toxicology;  
3) Contract Research;  
4) New Biotechnology in Drug Development;  
5) Latest Development in Clinical Trials; and  
6) Gene Therapy.

**Curriculum Vitae**

**Ruiwen Zhang, M.D., Ph.D., D.A.B.T.**

**Page 15**

1996

Invited Speaker: **Sino-US workshop, Advances in Clinical Trials.**  
Shanghai Institute of Planned Parenthood Research, Shanghai, China;  
September 26-29. Presentations included:  
1) GLP in Preclinical Pharmacology and Toxicology;  
2) Contract Research Organization; and  
3) Comparison of Drug Regulatory System in USA and China.

1995

**International Conference “Therapeutic Oligonucleotides From Cell To Man”:** Comparative Pharmacokinetics of Oligonucleotide and Modified Analogs. Seillac, FRANCE, April.

1994

**The 6th International Conference on Chronopharmacology and Chronotherapeutics:** Chronobiology of Thymidine Kinase and its Application in Cancer Chemotherapy. Amelia Island, FL, July.

## GRANT SUPPORT

### Current Funding ---- NIH/DoD

1. NIH/NCI (N01-CM-47015-45; HHSN261200522007C): Preclinical pharmacological studies of antitumor and other therapeutic agents". **PI: Ruiwen Zhang, M.D., Ph.D.** (25% effort); 12/15/04-12/31/2011 (This award is the competitive renewal application of N01-CM-07111; 12/1/99-12/15/2004). Annual budget: \$212,006 (Total budget \$1,714,794).
2. NIH/NCI (R01 CA 112029): MDM2 as a Negative Regulator of p21<sup>waf1/cip1</sup>. **PI: Ruiwen Zhang, M.D., Ph.D.** (20% effort); 01/01/05-12/31/2009; Annual budget 267,064 (Total budget 1,340,856).
3. NIH/NCI (N01CN85183): Randomized, double blind, placebo controlled phase II trial of celecoxib in subjects with actinic keratoses. **PI: Craig Elmets, M.D., Pharmacology** **PI: Ruiwen Zhang, M.D., Ph.D.** (5% effort); 9/30/98-10/01/2004.
4. NIH (R01 CA 86172): Phthalocyanine PDT: In Vivo Responses and Mechanisms. **P.I.: Craig A. Elmets, M.D.** **Co-Investigator: Ruiwen Zhang, M.D., Ph.D.** (10% effort); 03/01/2000-02/28/2005.
5. DoD Prostate Cancer Research Program (W81XWH-04-1-0845): MDM2 as a Target for Prostate Cancer Prevention and Therapy (Post-Doctoral Training Award). **Mentor: Ruiwen Zhang, M.D., Ph.D.**, Post-Doc: Zhang Z, MD, PhD, 09/30/04-10/01/06 (total budget \$125,00)
6. NIH/NCI (R01 CA104035): A novel inhibitor of Stat3 for prostate cancer therapy. **P.I.: Jing, Naijie, Ph.D.**, **Co-Investigator: Ruiwen Zhang, M.D., Ph.D.** (5% effort); 04/01/2005-03/31/2010. (This funding is anticipated: primary score 178, percentile 3.9).

### **Current Funding ---- Industry and Other Sources**

1. Hybridon, Inc.: Disposition of Oligonucleotides: Pharmacology and Toxicology. **PI: Ruiwen Zhang, M.D., Ph.D.** (30% effort); 08/01/93-07/31/2005 (Annual budget \$160,000; total budget \$2,040,000.)
2. NCCN: A Phase I and Pharmacologic Trial of Sequential Administration of Bi-weekly Gemcitabine as a 24-hour IV infusion followed by Irinotecan as a 24-hour IV Infusion in Adult Cancer Patients. **PI: M. Wasif Saif, M.D.** **Co-PI: Ruiwen Zhang, M.D., Ph.D.** (5% effort); 1/28/2003-1/27/2006. (Pharmacology budget \$140,000)
3. Eli Lilly and Co.: Dexamethasone in Lung Cancer. **P.I.: John J. Rinehart, M.D.**, **Co- P.I.: Ruiwen Zhang, M.D., Ph.D.** (15% effort); 03/01/2003-02/28/2007.

**Pending Funding:**

1. Congressionally Directed Research: Experimental Therapeutics targeting Angiogenesis. **P.I.: Ruiwen Zhang, M.D., Ph.D.** (20% effort); 01/01/2005-12/31/2006

**Past Funding**

1. NIH/NCI (CA-40530): Mechanism of Toxicity of Fluoropyrimidines. PI: Robert B. Diasio, M.D., **Co-PI: Ruiwen Zhang, M.D., Ph.D.** (20% effort); 7/1/88-6/30/96; \$1,055,458.
2. American Cancer Society: Clinical Investigation of Dihydropyrimidine Dehydrogenase in Cancer Patients. PI: Robert B. Diasio, M.D., **Co-PI: Ruiwen Zhang, M.D., Ph.D.** (15% effort); 01/01/94-12/31/95; \$150,000.
3. NIH/NCI (CA 62164): Genetic Polymorphism of Dihydropyrimidine Dehydrogenase. PI: Robert B. Diasio, M.D., **Co-PI: Ruiwen Zhang, M.D., Ph.D.** (20% effort); 12/09/93-11/30/97; \$942,193.
4. Biocryst, Inc.: Plasma- and Serum-Protein Binding of BCX-34. **PI: Ruiwen Zhang, M.D., Ph.D.** (5% effort); 10/1/95-9/30/96; \$10,000.
5. SmithKline Beecham, Inc.: Phase I/IIa Study of Sequential Ifosfamide and Topotecan in Patients with Small Cell Lung Cancer. PI: Francisco Robert, M.D., **Co-Investigator: Ruiwen Zhang, M.D., Ph.D.** 01/01/97-12/31/99; \$40,000.
6. Eli Lilly and Co/Lilly Oncology: Phase I/IIa Study of Cisplatin, Dexamethasone and a 24-hour infusion of Gemcitabine in patients with relapsed or Refractory Non-Hodgkin's Lymphoma. PI: Francisco Robert, M.D., **Co-Investigator: Ruiwen Zhang, M.D., Ph.D.** 12/01/97-12/31/99; \$75,000.
7. Ontario Ministry of Health, Canada: Clinical Study of Time-dependent Therapeutic Effects and/or Toxicity of Zidovudine (AZT) in AIDS Patients. PI: Georg A. Bjarnason, M.D.; **Co-Investigator: Ruiwen Zhang, M.D., Ph.D.** 12/01/97-12/31/99; \$286,600
8. Rhone-Poulenc Rorer: Phase I Dose Escalation Study of Taxotere and Continuous Infusion of Topotecan in Patients with Advanced Malignancies. PI: James A. Posey, M.D., **Co-Investigator: Ruiwen Zhang, M.D., Ph.D.**, 05/01/98-4/30/00; \$101,232
9. IDEC Pharmaceuticals, Inc. (IDEC132-01 Phase I): Phase I Study of 9-Amino-camptothecin in Patients with Solid Tumors (Pharmacology Study). **PI: Ruiwen Zhang, M.D., Ph.D.** (5% effort); 12/01/97-11/31/2000; \$178,046.

**Curriculum Vitae**

**Ruiwen Zhang, M.D., Ph.D., D.A.B.T.**

Page 18

10. NIH/NCI (N01 CN65024): A Phase II Trial of Sulindac in Patients with Cervical Intraepithelial Neoplasia (CIN) Grade 3 -Histological Reduction of CIN 3 and Modulation of Surrogate Endpoint Biomarkers. PI: Ronald Alvarez, M.D., **Pharmacology PI: Ruiwen Zhang, M.D., Ph.D.** (5% effort) 09/30/96-9/29/98; \$629,074 (Extension to 10/1/2001 with additional support).
11. IDEC Pharmaceuticals, Inc.: Phase II Study of 9-Aminocamptothecin in Patients with Solid Tumors (Pharmacokinetics/ Pharmacodynamics Study). **PI: Ruiwen Zhang, M.D., Ph.D.** (5% effort); 05/01/98-4/30/2001; \$37,870.
12. NIH/NCI (U01CA76607): Therapeutic Studies of Anaplastic Gliomas. PI: Steven Rosenfeld, M.D., **Co-Investigator: Ruiwen Zhang, M.D., Ph.D.**, 04/01/98-3/31/2002; Yearly Costs: \$102,923.
13. NIH/NCI: Evaluation of Chemopreventive Agents by in vitro Techniques. (NCI-CN-85093-63). PI: Donald Hill, Ph.D., **Co-PI: Ruiwen Zhang, M.D., Ph.D.**; 7/1/99-6/30/2003. (Master Agreement)
14. NIH/NCI (R01 CA 80698): MDM2 Oncogene as a Target for Modulating Cancer Therapy. **PI: Ruiwen Zhang, M.D., Ph.D.** (30% effort); 04/01/99-3/31/2004; \$997,298.
15. NIH: Breast Cancer SPORE. P.I.: K Bland, M.D. (P50 CA89019), **Co-Investigator: Ruiwen Zhang, M.D., Ph.D.** (5% effort); 03/01/2000-02/28/2005.
16. Industrial Sponsor: Pre-clinical Evaluation of Antisense Anti-XIAP Oligonucleotides in PC-3 Model. **PI: Ruiwen Zhang, M.D., Ph.D.** (5% effort). 11/01/2002-10/30/2003.
17. NIH/NCI: Preclinical Pharmacological Studies of Antitumor and Anti-HIV Agents. (N01-CM-07111). **PI: Ruiwen Zhang, M.D., Ph.D.** (15% effort); 12/1/99-12/15/2004.

## **PATENTS**

1. **A method for down-regulating gene expression.** (US Patent No 5, 591,721)
2. **Use of 2'-substituted oligonucleotides to down-regulate gene expression.** (European Patent Serial No. 95938213.6)
3. **MDM2-Specific Antisense Oligonucleotides** (US Patent No. 6,013,786)
4. **Methods of down-regulating gene expression.** (US Patent No. 6,608,035)
5. **Down-regulation of gene expression by colorectal administration of synthetic oligonucleotides.** (US patent filed, No. 08/846, 427, 04/30/97)

## BIBLIOGRAPHY

### MANUSCRIPTS ALREADY PUBLISHED

1. **Zhang R**, Zhang R-W, Jiang X, Wang Y, Chao X, Wu Y. The background values of chlordimeform and its metabolites in urine of general population. *Occup Med* 1985; 12(4): 7-9.
2. Chen Z, **Zhang R**, Qiu J, Pan Z. Effects of occupational lead exposure on workers' health. *Chin J Prevent Med* 1985; 9(4): 216-219.
3. Zhang R-W, Zhu G, Liu Z, Yang Y, Qiu J, Sheng Y, **Zhang R**. Spectrophotometric determination of air lead with tetra-(p-trimethylammoniumphenyl) porphyrin. *J Labor Med* 1985; 2(1): 61-63.
4. Zhu G, Zhang R, Yang Y, **Zhang R**, Sheng Y, Qiu J, Liu Z. Spectrophotometric determination of urinary lead with tetra-(p-trimethylammoniumphenyl) porphyrin. *J Labor Med* 1985; 2(2): 79-82.
5. Tao X, Sun Y, Wang M, Xue S, **Zhang R**, Jiang X, Wang Y. The investigation of health effects on workers exposed to chlordimeform. *Chin J Ind Hyg Occup Dis* 1985; 3(5): 272-274.
6. Li F, **Zhang R**, Jiang X, Xue S, Wang Y. Overview on the carcinogenicity, mutation, and teratogenicity of chlordimeform. *Occup Med* 1985; 12(3): 39-42.
7. Xue S, **Zhang R**. Overview on sister chromatid exchanges (SCE) as a monitoring index for occupational exposure to chemicals. *J Labor Med* 1985; 2(2): 66-71.
8. **Zhang R**, Xue S, Wang Y. Measurement of pesticide contamination on body surface of sprayers through regional and proportional sampling strategy. *Occup Med* 1986; 13(3): 2-4.
9. Lin W, **Zhang R**, Gu Z, Wang X, Zhang R-W, Jiang X, Xue S, Wang Y. Urinary chlordimeform and its metabolites as a monitoring index for occupational exposure to chlordimeform. *Occup Hlth Railroad* 1986; 1: 14-17.
10. **Zhang R**, Lin W, Wang X, Gu Z, Qiu J, Xue S, Wang Y. Health effects of chlordimeform in exposed sprayers. *Chin J Prevent Med* 1986; 20(3): 186-187.
11. Wang X, **Zhang R**, Gu Z, Lin W, Xue S. Occupational chlordimeform poisoning: Case report. *J Labour Med* 1986; 3(2): 9-11.
12. Chen Z, Fi H, **Zhang R**, Qiu J, Pan Z. The study of zinc protoporphyrin as a screening index for occupational hazards of lead. *Natl Med J China* 1986; 66(8): 484-487.

13. Pan Z, Qiu J, **Zhang R**, Chen Z, Gu J, Xue S, Wang Y. The study of blood lead and free protoporphyrin as screening indices of occupational exposure to lead, an example of application of discriminant analysis. *Chin J Ind Hyg Occup Dis* 1986; 4(3): 144-147.
14. Wang M, Zhou Z, Li H, **Zhang R**, Xue S. Risk assessment of occupational exposure to chlordimeform. *Chin J Ind Hyg Occup Dis* 1987; 5(1): 50-53.
15. Zhu Q, Liu L, **Zhang R**, Wang Y. Overview on the heme biosynthetic pathway and hemoprotein as indicator of exposure to toxic agents. *Intl Med (Pub Hlth)* 1988; 2: 65-69.
16. **Zhang R**, Wang Y, Zhang R, Li H, Jiang X. Urinary formic acid in employees exposed to formaldehyde. *Occup Med* 1988; 15(5): 55-57.
17. **Zhang R**, Wang Y, Li H, Jiang X. Monitoring of urinary formic acid in formaldehyde exposed workers. *Railway Occup Safety Hlth Environ Protect* 1988; 4: 50-53.
18. **Zhang R**, Jiang X. Hepatotoxicity of formaldehyde. *J Hlth Toxicol* 1988; 3(2): 18-22.
19. **Zhang R**, Li H, Zhang RW, Jiang X. Study of the applicability of urinary formic acid as a biological monitoring indicator for formaldehyde exposure. In: Xue S and Liang Y (eds): *Occupational Health in Industrialization and Modernization*, Shanghai Medical University Press, 1988: pp. 128-131.
20. **Zhang R**, Jiang X. A preliminary report on the analysis of malignant mortality among faculty members and staff in departments of anatomy of medical schools in Shanghai. In: Xue S and Liang Y (eds): *Occupational Health in Industrialization and Modernization*, Shanghai Medical University Press, 1988: pp. 89-90.
21. Jiang X, **Zhang R**. The studies on potential risk of occupational exposure to formaldehyde. In: Xue S and Liang Y (eds): *Occupational Health in Industrialization and Modernization*, Shanghai Medical University Press, 1988; pp. 70-74.
22. Xue S, Wang M, Jiang X, Li F, **Zhang R**, Zhou Z, Gu X. Risk assessment of Occupational exposure to chlordimeform. In: Xue S and Liang Y (eds): *Occupational Health in Industrialization and Modernization*, Shanghai Medical University Press, 1988; pp. 34-36.
23. Wang Y, **Zhang R**, Jiang X. Inhalation of formaldehyde: toxicology, epidemiology, and control. *Occup Med* 1989; 16(2): 40-44.
24. Yu J, Qiu J, **Zhang R**, Xue S. The determination of serum monoamine oxidase activity and its application in exposure assessing for chlordimeform. *Chin J Ind Hyg Occup Dis* 1989; 7(2): 10-12.
25. Jiang X, **Zhang R**. Survival effects in cross-section study. *J Labour Med* 1989; 6(1): 1-4.

26. **Zhang R**, Jiang X, Pan X. Effects on erythrocytes membrane fluidity of formaldehyde and its metabolites, formic acid. *J Hlth Toxicol* 1989; 4(2): 8-11.
27. **Zhang R**, Jiang X. Work-related diseases among employees exposed to formaldehyde. *Chin J Ind Hyg Occup Dis* 1989; 7(5): 284-289.
28. **Zhang, R.** Toxicity of pesticide. In: Gong Z et al (eds): *Occupational Health and Safety*, Shanghai Labour Press, Shanghai, 1989.
29. **Zhang R**, Wang Y, Jiang X. Metabolism of formaldehyde in erythrocyte and hepatocyte. *J Hlth Toxicol* 1990; 4(1): 7-9.
30. Jiang X, **Zhang R**, Lu P, Wang Y, Gu X. Cancer mortality among workers exposed to formaldehyde. *Chin J Ind Hyg Occup Dis* 1990; 8(5): 261-264.
31. **Zhang R**, Jiang X, Wu Y. Hepatotoxicity of formaldehyde observed in perfused mice livers and in culture of rat hepatocyte. *Acta Academiae Medicinae Shanghai* 1990; 17(2): 149-152.
32. Jiang X, **Zhang R**, Wang Y, Yuan J. Pulmonary effects of chronic exposure to formaldehyde. *Chin Ind Med* 1990; 3: 12-15.
33. Daher GC, Harris BE, **Zhang R**, Willard EM, Soong S-j, Diasio RB. The role of dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (dThdPase) in the circadian variation of plasma drug levels of 5-fluorouracil (FUra) and 5-fluoro-2'-deoxyuridine (FdUrd) following infusion of FUra and FdUrd. *Ann Rev Chronopharm* 1990; 227-230.
34. Daher GC, **Zhang R**, Soong S-j, Diasio RB. Circadian variation of pyrimidine catabolizing enzymes in rat liver: Possible relevance to 5-fluorodeoxyuridine chemotherapy. *Drug Metab Disp* 1991; 19 (1): 285-287.
35. Daher GC, Nagib FNM, el Kouni MH, **Zhang R**, Soong S-j, Diasio RB. Inhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil: possible relevance to regional chemotherapy. *Biochem Pharm* 1991; 41(12): 1887-1893.
36. **Zhang R**, Barnes S, Diasio RB. Disposition and metabolism of 2-fluoro- $\beta$ -alanine conjugates of bile acids following secretion into bile. *Biochim Biophys Acta* 1991; 1096: 179-186.
37. **Zhang R**, Soong S-j, Liu T, Barnes S, Diasio RB. Pharmacokinetics and tissue distribution of 2-fluoro- $\beta$ -alanine: Possible relevance to toxicity pattern of 5-fluorouracil. *Drug Metab Disp* 1992; 20 (1): 113-119.
38. **Zhang R**, Barnes S, Diasio RB. Differential intestinal deconjugation of taurine- and glycine-conjugated bile acid N-acyl amides in rats. *Am J Physiol* 1992; 262: G351-G358.

39. Lu Z, **Zhang R**, Diasio RB. Purification and characterization of dihydropyrimidine dehydrogenase from human liver. *J Biol Chem* 1992; 267 (24): 17102-17109.
40. **Zhang R**, Lu Z, Liu T, Soong S-j, Diasio, RB. Circadian rhythm of rat spleen cytoplasmic thymidine kinase. *Biochem Pharm* 1993; 45 (5): 1115-1119.
41. **Zhang R**, Liu T, Soong S-j, Diasio RB. A mathematical model of kinetics and disposition of 2-fluoro- $\beta$ -alanine, the major metabolite of 5-fluorouracil. *Biochem Pharm* 1993; 45 (10): 2063-2069.
42. **Zhang R**, Lu Z, Liu T, Soong S-j, Diasio RB. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes. Possible relevance to fluoropyrimidine chemotherapy. *Cancer Res* 1993; 53: 2816-2822.
43. **Zhang R**, Lu Z, Diasio, CR, Liu T, Soong S-j. The time of administration of 3'-azido-3'-deoxythymidine (AZT) determines its host toxicity with possible relevance to AZT chemotherapy. *Antimicrob Agents Chemother* 1993; 37 (9): 1771-1776.
44. Sparano JA, Wadler S, Diasio RB, **Zhang R**, Lu Z, Schwartz EL, Einzig A, Wiernik PH. A phase I trial of low-dose, prolonged continuous infusion 5-fluorouracil plus interferon- $\alpha$ : Evidence for enhanced 5-fluorouracil toxicity without pharmacokinetic perturbation. *J Clin Oncol* 1993; 11: 1609-1617.
45. Lu Z, **Zhang R**, Diasio RB. Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver: Biochemical and Immunological properties. *Biochem Pharm* 1993; 46 (5): 945-952.
46. Lu Z, **Zhang R**, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. *Cancer Res* 1993; 53: 5433-5438.
47. **Zhang R**, Diasio RB, Lu Z, Liu TP, Jiang Z, Galbraith W, Agrawal S. Pharmacokinetics and tissue distribution of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus infection. *Biochem Pharm* 1995; 49: 929-939.
48. **Zhang R**, Yan J, Shahinian H, Amin G, Lu Z, Liu, T, Saag, MS, Jiang Z, Temsamani J, Martin RR, Schechter P, Agrawal S, Diasio RB. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. *Clin Pharmacol Ther* 1995; 58: 44-53.
49. **Zhang R**, Lu Z, Zhao H, Zhang X, Diasio RB, Habus I, Jiang Z, Iyer RP, Yu D, Agrawal S. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats. *Biochem Pharm* 1995; 50: 545-556.

50. **Zhang R**, Lu Z, Zhang X, Zhao H, Diasio RB, Jiang Z, Agrawal S. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats. *Clin Chem* 1995; 41: 836-843.
51. Agrawal S, Zhang X, Zhao H, Lu Z, Yan J, Cai H, Diasio RB, Habus I, Jiang Z, Iyer RP, Yu D, **Zhang R**. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. *Biochem Pharm* 1995; 50: 571-576.
52. Diasio RB, Van Kuilenburg ABP, Lu Z, **Zhang R**, Van Lenthe H, Bakker HD, Van Gennip AH. Determination of dihydropyrimidine dehydrogenase (DPD) in fibroblasts of a DPD deficient pediatric patient and family members using a polyclonal antibody to human DPD. In: Purine and Pyrimidine Metabolism in Man VIII, Edited by Sahota A and Taylor M. pp. 7-10, Plenum Press, New York, 1995.
53. Lu Z, **Zhang R**, Diasio RB. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, A key metabolic enzyme in 5-fluorouracil chemotherapy. *Clin Pharmacol Ther* 1995; 58: 512-522.
54. Zhang X, **Zhang R**, Zhao H, Cai H, Gush KA, Kerr RG, Pettit GR, Kraft AS. Preclinical pharmacology of the natural product anticancer agent Bryostatin 1, an activator of protein kinase C. *Cancer Res* 1996; 56: 802-808.
55. Takimoto C, Lu Z, **Zhang R**, Liang M, Larson L, Grem JL, Allegra CL, Diasio RB, Chu E. Severe Neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. *Clin Cancer Res* 1996; 2:477-481.
56. **Zhang R**, Iyer P, Yu D, Tan W, Zhang X, Lu Z, Zhao H, Agrawal S. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleotide phosphorothioate in rats following intravenous administration. *J Pharm Exp Ther* 1996; 278: 971-979.
57. Li Y, **Zhang R**. Reversed-phase high-performance liquid chromatography method for the simultaneous quantitation of the lactone and carboxylate forms and the metabolites of the novel natural product anticancer agent 10-hydroxycamptothecin in biological fluids and tissues. *J Chromatogr B Biomed Appl*, 1996; 686: 257-265.
58. Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, Channavajjala L, Saxinger C, **Zhang R**. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. *Proc Natl Acad Sci USA* 1997; 94: 2620-2625.
59. Cai Q, Lindsey JR, **Zhang R**. Regression of human colon cancer xenografts in SCID mice following oral administration of water-insoluble camptothecins, natural product topoisomerase I inhibitors. *Intl J Oncol* 1997; 10: 953-960

60. Agrawal S, Tan W, Cai Q, Xie X, **Zhang R**. In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines. *Antisense Nucleic Acid Drug Dev* 1997; 7: 245-249.
61. **Zhang R**, Cai Q, Lindsey JR, Li Y, Chambliss B, Naguib FNM. Antitumor activity and pharmacokinetics following oral administration of natural product DNA topoisomerase I inhibitors 10-hydroxycamptothecin and camptothecin in SCID mice bearing human breast cancer xenografts. *Intl J Oncol* 1997; 10:1147-1156.
62. Cai Q, Rahn RO, **Zhang R**. Dietary flavonoids quercetin, luteolin, and genestein reduce oxidative DNA damage and lipid peroxidation and quench free radicals. *Cancer Lett* 1997; 119: 99-107.
63. Diasio RB and **Zhang R**, Pharmacology of Therapeutic Oligonucleotides. *Antisense Nucleic Acid Drug Dev* 7: 239-243, 1997.
64. Agrawal S, Zhang X, Cai Q, Zhao H, Tan W, Yu D, **Zhang R**. Effect of aspirin on pharmacokinetics of antisense oligonucleotides in rats. *J Drug Targeting* 1998; 5: 303-312.
65. Chen L, Agrawal S, Zhou W, **Zhang R**, Chen J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. *Proc Natl Acad Sci USA* 1998; 95: 195-200.
66. **Zhang R**, Li Y, Cai Q, Liu T, Sun H, Chambliss B. Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I. *Cancer Chemother Pharm* 1998; 41: 257-267.
67. Lu Z, **Zhang R**, Carpenter JT, and Diasio RB. Decreased dihydropyrimidine dehydrogenase activity in population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. *Clin Cancer Res* 1998; 4: 325-329.
68. Liu W, **Zhang R**. Upregulation of p21/WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer agents 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways. *Intl J Oncol* 1998; 12: 793-804.
69. Chen L, Lu W, Agrawal S, Zhou W, **Zhang R**, Chen J. Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression. *Molecular Medicine*. 1999; 5: 21-34.
70. Wang H, Zeng X, Oliver P, Le LP, Chen J, Chen L, Zhou W, Agrawal S, **Zhang R**. MDM2 oncogene as a target for cancer therapy: An antisense approach. *Int J Oncol* 1999; 15: 653-660.
71. Wang H, Cai Q, Zeng X, Yu D, Agrawal S, **Zhang R**. Anti-tumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to RI $\alpha$  subunit of protein kinase A after oral administration. *Proc Natl Acad Sci USA* 1999; 96: 13989-13994.

72. **Zhang R** and Wang H. MDM2 Oncogene as a Novel Target for Human Cancer Therapy. *Current Pharmaceutical Design* 6: 393-416, 2000.
73. **Zhang R** and Wang H. Antisense Oligonucleotides as Anticancer Therapeutics. *Recent Research Development in Cancer*, 2: 61-76, 2000.
74. Platzer P, Thalhammer T, Reznicek G, Hamilton G, **Zhang R**, Jager W. Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver. *Int J Oncol* 2001; 19: 1287-1293.
75. Wang H, Nan L, Yu D, Agrawal S, **Zhang R**. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: In vitro and in vivo activities and mechanisms. *Clin Cancer Res* 2001; 7: 3613-3624.
76. Wang H, Prasad G, Buolamwini JK, and **Zhang R**. Antisense Anticancer Oligonucleotide Therapeutics. *Curr Cancer Drug Targets* 2001; 1: 177-196.
77. Wang H, Wang S, Nan L, Yu D, Agrawal S, **Zhang R**. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: *In vivo* activity and mechanisms. *Int J Oncol* 2002; 20: 745-752.
78. Prasad G, Wang H, Agrawal S, **Zhang R**. Antisense Oligonucleotides Targeted to MDM2 Oncogene as a Novel Approach to The Treatment of Glioblastoma Multiforme. *Anticancer Res* 2002; 22: 107-116.
79. Wang H, Nan L, Yu D, Lindsey JR, Agrawal S, **Zhang R**. Anti-tumor Efficacy of A Novel Antisense Anti-mdm2 Mixed-Backbone Oligonucleotide in Human Colon Cancer Models: p53-Dependent and p53-Independent Mechanisms. *Mol Med* 2002; 8: 185-199.
80. Wang H, Oliver P, Nan L, Wang S, Wang Z, Rhie J. K., **Zhang R**, Hill D. Radiolabeled 2'-Fluorodeoxyuracil- $\beta$ -D-arabinofuranoside (FAU) and 2'- Fluoro-5-methydeoxyuracil- $\beta$ -D-arabinofuranoside (FMAU) are tumor – imaging agents in mice. *Cancer Chemother Pharm* 2002; 49: 419-424.
81. Wang H, Hang J, Shi Z, Li M, Yu D, Kandimalla ER, Agrawal S, **Zhang R**. Antisense oligonucleotide targeted to RI alpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: *In vivo* synergistic activity, pharmacokinetics and host toxicity. *Int J Oncol* 2002; 21: 73-80.
82. Robert F, Spencer SA, Childs HA, **Zhang R**, Meredith RF, Wheeler RH, Hawkins MH, Carey D. Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial. *Lung Cancer* 2002; 37:189-199.

83. Yu D, Zhu F-G, Bhagat L, Wang H, Kandimalla ER, **Zhang R**, Agrawal S. Potent CpG oligonucleotides containing phosphodiester linkages: *in vitro* and *in vivo* immunostimulatory properties. *Biochem Biophys Res Comm* 2002; 297: 83-90.
84. Bhagat L, Zhu F, Yu D, Tang J, Wang H, Kandimalla ER, **Zhang R**, Agrawal S. CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. *Biochem Biophys Res Comm* 2003; 300: 853-861.
85. Wang H, Yu D, Agrawal S, **Zhang R**. Experimental Therapy of Human Prostate Cancer by Inhibiting MDM2 Expression with Novel Mixed-Backbone Antisense Oligonucleotides: *In Vitro* and *In Vivo* Activities and Mechanisms. *Prostate* 2003; 54: 194-205.
86. **Zhang R** and Wang H. Antisense Oligonucleotides Targeting RI $\alpha$  Subunit of Protein Kinase A; *In vitro* and *In vivo* Antitumor Activity and Pharmacokinetics. *Methods Mol Med* 2003; 75: 637-654.
87. **Zhang R** and Wang H. Antisense Oligonucleotide Inhibitors of MDM2 Oncogene Expression. *Methods Mol Med* 2003; 85: 205-222.
88. Kandimalla ER, Bhagat L, Wang D, Yu D, Zhu F, Tang J, Wang H, Huang H, **Zhang R**, Agrawal S. Divergent Synthetic Nucleotide Motif Recognition Pattern: Design and Development of Potent Immunomodulatory Oligodeoxyribonucleotide Agents with Distinct Cytokine Induction Profiles. *Nucleic Acid Res.* 2003; 31: 2393-2400.
89. Zhang Z, Li M, Wang H, Agrawal S, **Zhang R**. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. *Proc Natl Acad Sci U S A*. 2003; 100:11636-11641.
90. Mani S, Goel S, Martin RM, Grindel JM, Rothenberg ML, **Zhang R**, Tortora G, Cho-Chung YS. Clinical study in patients with solid tumors using a second-generation oligonucleotide (GEM231®) targeting the type I protein kinase A mRNA. *Ann New York Acad Sci* 2003; 1002: 252-262.
91. Wang H, Oliver P, Zhang Z, Agrawal S, **Zhang R**. Chemosensitization and Radiosensitization of Human Cancer by Antisense Anti-MDM2 Oligonucleotides: *In vitro* and *In vivo* Activities and Mechanisms. *Ann New York Acad Sci* 2003; 1002: 217-235.
92. Prasad G, Wang H, Hill DL, **Zhang R**. Recent advances in experimental molecular therapeutics for malignant gliomas. *Curr Med Chem-Anti-Ca Agents* 2004; 4: 347-361.
93. Luu HH, **Zhang R**, Haydon RC, Rayburn E, Kang Q, Si W, Park JK, Wang H, Peng Y, Jiang W, He T-C. Wnt/ $\beta$ -Catenin signaling pathway as a novel cancer drug target. *Curr Cancer Drug Targets*, 2004; 4; 653-671.

**Curriculum Vitae**

Ruiwen Zhang, M.D., Ph.D., D.A.B.T.

Page 27

94. Zhang Z, Wang H, Prasad G, Li M, Yu D, Bonner J, Agrawal S, **Zhang R**. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in *in vitro* and *in vivo* human cancer models. *Clin Cancer Res*. 2004; 10: 1263-1273.
95. Wang H, Li M, Rinehart JJ, **Zhang R**. Pretreatment with Dexamethasone Increases Antitumor Activity of Carboplatin and Gemcitabine in Mice Bearing Human Cancer Xenografts: *In Vivo* Activity, Pharmacokinetics and Clinical Implications for Cancer Chemotherapy. *Clin Cancer Res*. 2004; 10: 1633-1644.
96. Wang H, Li M, Rinehart JJ, **Zhang R**. Dexamethasone as a chemoprotectant in cancer chemotherapy: Hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine. *Cancer Chemother Pharm* 2004; 53: 459-467.
97. Zhang Z, Wang H, Li M, Agrawal S, Chen X, **Zhang R**. MDM2 is a negative regulator of p21<sup>WAF1/CIP1</sup>, independent of p53. *J Biol Chem* 2004; 279: 16000-16006.
98. Zhang Z, **Zhang R**. p53-Independent Activities of MDM2 and Their Relevance to Cancer Therapy. *Curr Cancer Drug Targets* 2005; 5: 9-20.
99. **Zhang R**, Wang H, Agrawal S. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: Proof of principle, *in vitro* and *in vivo* activities, and Mechanisms. *Curr Cancer Drug Targets* 2005; 5: 43-50.
100. Rayburn E, **Zhang R**, He J, Wang H. MDM2 and Human Malignancies: Expression, Clinical Pathology, Prognostic Markers, and Implications for Chemotherapy. *Curr Cancer Drug Targets* 2005; 5: 27-42.
101. Rayburn E, Wang H, He J, **Zhang R**. RNA silencing technologies in drug discovery and target validation. *Letters in Drug Design and Discovery* 2005; 2: 1-18.
102. Posey JA, Wang H, Hamilton J, Delgrossio A, **Zhang R**, Freda T, Zamboni WC. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. *Cancer Chemother Pharmacol*. 2005 Apr 19; [Epub ahead of print]
103. Wang H, Li M, Rhie JK, Covey J, Hockenberry DM, **Zhang R**, Hill D. Preclinical pharmacology of 2-Methoxyantimycin A compounds as novel antitumor agents. *Cancer Chemother Pharm* 2005 May 10; [Epub ahead of print]
104. **Wang H, Wang Z, Wang S, Li M, Nan L, Rhie JK, Covey JM, Zhang R, Hill DL**. Preclinical pharmacology of Epothilone D, a novel tubulin-stabilizing antitumor agent. *Cancer Chemother Pharm* 2005 May 3; [Epub ahead of print]
105. Wang H, Rayburn E, Hill D, **Zhang R**. Synthetic Oligodeoxynucleotides Containing Deoxycytidyl-Deoxyguanosine Dinucleotides (CpG ODNs) and Modified Analogs as Novel Anti-cancer Therapeutics. *Curr Pharm Design* (in press)

106. Zhang Z, Li M, Rayburn E, Hill DL, **Zhang R**, Wang H. Oncogenes as Novel Targets for Cancer Therapy (Part I): Growth Factors and Protein Tyrosine Kinases. *Am J Pharmacogenomics* (in press)
107. Zhang Z, Li M, Rayburn E, Hill DL, **Zhang R**, Wang H. Oncogenes as Novel Targets for Cancer Therapy (Part II): Intermediate Signaling Molecules. *Am J Pharmacogenomics* (in press)
108. Zhang Z, Li M, Rayburn E, Hill DL, **Zhang R**, Wang H. Oncogenes as Novel Targets for Cancer Therapy ((Part III): Transcription. *Am J Pharmacogenomics* (in press)
109. Zhang Z, Li M, Rayburn E, Hill DL, **Zhang R**, Wang H. Oncogenes as Novel Targets for Cancer Therapy (Part IV): Regulators of the Cell Cycle, DNA Damage Repair and Apoptosis. *Am J Pharmacogenomics* (in press)
110. Zhang Z, Wang H, Li M, Agrawal S, **Zhang R**. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. *Oncogene* (in press).
111. Li M, Zhang Z, Wang H, Hill D, Chen X, **Zhang R**. Genistein down-regulates MDM2 expression independent of p53, a previously unrecognized mechanism of action. *Cancer Research* (In revision).

## OTHER PUBLICATIONS

1. **Zhang R**. Circadian based infusional chemotherapy. *J Infusional Chemotherapy*, 4: 67-68, 1994.
2. **Zhang R**. Preface. *Curr Cancer Drug Targets* 2001; 1 (3), i.
3. **Zhang R**. Editorial. *Curr Cancer Drug Targets* 2005; 5 (1), 1-2.

## BOOKS (BOOKS AND BOOK CHAPTERS)

1. **Zhang R**. Methodology of Occupational Epidemiology. In: *Occupational Epidemiology* (Gu X et al ed.), Shanghai Medical University Press, 1984, pp. 94-108.
2. **Zhang R**. History, Philosophy, and Perspectives of Exposure Limits. In: *Ann Health Standard* (Liang Y et al ed.), Shanghai Medical University Press, 1985, pp. 122-128.
3. **Zhang R**. History and Perspectives of Toxicology. In: *Toxicology Evaluation* (Liang Y et al ed.), Shanghai Medical University Press, 1985, pp. 4-8.
4. **Zhang R**. The Importance of Pharmacokinetics and Macromolecule in the Study of Carcinogenesis and Risk Assessment. In: *Toxicology Evaluation* (Liang Y et al ed.), Shanghai Medical University Press, 1985, pp. 48-59.

5. **Zhang R.** Occupational Health in the Professional Women. In: *Occupational Health in Working Women* (Lu Q et al ed.), Shanghai Medical University Press, 1985, pp.36-41.
6. **Zhang R.** Primary Health in Women Occupational Health. In: *Occupational Health in Working Women* (Lu Q et al ed.), Shanghai Medical University Press, 1985, pp. 42-43.
7. **Zhang R.** Future Studies needed in Occupational Health, In: *Occupational Health in Working Women* (Lu Q et al ed.), Shanghai Medical University Press.1985, pp.45-46.
8. **Zhang R.** Absorption, Distribution, and Excretion of Toxicants. In: *Basic Toxicology* (Jiang X et al ed.), Shanghai Medical University Press, 1986, pp. 10-15.
9. **Zhang R.** Toxicology Evaluation.In: *Basic Toxicology* (Jiang X et al ed.), Shanghai Medical University Press, 1986, pp. 63-69.
10. **Zhang R.** Carcinogenesis. In: *Basic Toxicology* (Jiang X et al ed.), Shanghai Medical University Press, 1986, pp. 81-91.
11. **Zhang R.** Principles and Practice of Epidemiology. In: *Reproductive Medicine* (Jiang X et al ed.), Shanghai Press, 1991, pp. 200-226.
12. Jiang X and **Zhang R.** Methodology of reproductive epidemiology. In: *Reproductive Medicine* (Jiang X et al ed.), Shanghai Press, 1991, pp. 227-258.
13. Gu Z, **Zhang R**, Dong W. External fertilization and its application. In: *Reproductive Medicine* (Jiang X et al ed.), Shanghai Press, 1991, pp. 194-199.
14. Xu S, Jing X, **Zhang R.** Toxicity of Ether. In: *Encyclopedia of Chemical Toxicity* (Xia Y et al ed.), Shanghai Science and Technology Press, 1991, pp.437-440.
15. **Zhang R**, Diasio RB. Pharmacologic Basis for Circadian Pharmacodynamics. In: *Circadian Cancer Therapy* (Hrushesky WJM, ed.), CRC Press, 1994, pp. 61-103.
16. Diasio RB, Lu Z, **Zhang R**, Shihani, H. Fluoropyrimidine Catabolism. In: *Concepts, Mechanisms, and New Targets for Chemotherapy* (Muggia F, ed.) Kluwer Academic Publishers, Boston, MA, 1995, pp.71-93.
17. Zhou H and **Zhang R.** *Guide to Research and Development of New Drugs*. China Medical and Pharmaceutical Press, Beijing, 1997.
18. Agrawal S and **Zhang R**, Pharmacokinetics of Phosphorothioate Oligonucleotide and its Novel Analogs. In: *Antisense Oligodeoxynucleotides and Antisense RNA as Novel Pharmacological and Therapeutic Agents* (Weiss B. Ed.) CRC Press, 1997, pp. 58-78.

**Curriculum Vitae**

Ruiwen Zhang, M.D., Ph.D., D.A.B.T.

Page 30

19. Agrawal S and **Zhang R**, Pharmacokinetics of Oligonucleotides. In: *Oligonucleotides as Therapeutic agents* (Chadwick DJ and Cardew G, Eds.) Ciba Foundation Symposium 209, Wiley, Chichester, 1997, pp. 60-78.
20. Zhou H-J and **Zhang R**, Introduction. In: *Guide to Research and Development of New Drugs* (Zhou H and **Zhang R**, ed.), China Medical and Pharmaceutical Press, Beijing, 1997, pp. 1-9.
21. **Zhang R**, Non-clinical Study in Drug Development. In: *Guide to Research and Development of New Drugs* (Zhou H and **Zhang R**, ed.), China Medical and Pharmaceutical Press, Beijing, 1997, pp. 100-112.
22. **Zhang R**, Good Laboratory Practice in Non-clinical Studies. In: *Guide to Research and Development of New Drugs* (Zhou H and **Zhang R**, ed.), China Medical and Pharmaceutical Press, Beijing, 1997, pp. 113-130.
23. Lu Z and **Zhang R**, Animal Study in Drug Development. In: *Guide to Research and Development of New Drugs* (Zhou H and **Zhang R**, ed.), China Medical and Pharmaceutical Press, Beijing, 1997, pp. 131-150.
24. **Zhang R**, Contract Research in Drug Development. In: *Guide to Research and Development of New Drugs* (Zhou H and **Zhang R**, ed.), China Medical and Pharmaceutical Press, Beijing, 1997, pp. 167-182
25. **Zhang R**, Pharmaceutical Issues in Drug Development. In: *Guide to Research and Development of New Drugs* (Zhou H and **Zhang R**, ed.), China Medical and Pharmaceutical Press, Beijing, 1997, pp. 203-210.
26. Lu Z and **Zhang R**, Anti-HIV Therapeutics. In: *Guide to Research and Development of New Drugs* (Zhou H and **Zhang R**, ed.), China Medical and Pharmaceutical Press, Beijing, 1997, pp. 256-273.
27. **Zhang R** and Lu Z, Antimicrobial Therapeutics. In: *Guide to Research and Development of New Drugs* (Zhou H and **Zhang R**, ed.), China Medical and Pharmaceutical Press, Beijing, 1997, pp. 274-284.
28. Agrawal S and **Zhang R**, Pharmacokinetics and Bioavailability of Oligonucleotides following Oral and Colorectal Administrations in Experimental Animals. In: *Antisense Research and Applications* (Crooke S ed.), Springer-Verlag, Heidelberg, 1998; pp.525-543.
29. **Zhang R**. Guest editor, *Curr Cancer Targets*, Vol 1, Number 3, *Antisense Oligonucleotide Therapeutics*, November 2001.
30. **Zhang R**. Guest editor, *Curr Cancer Targets*, Vol 5, Number 1, *MDM2 As A Novel Cancer Drug Target*, February 2005

**Curriculum Vitae**

Ruiwen Zhang, M.D., Ph.D., D.A.B.T.

Page 31

31. **Zhang R** and Wang H. Modulation of Gene Expression by Antisense Oligonucleotides. In: S. W. Kim and R.I. Mahato eds: *Pharmaceutical Perspectives of Nucleic acid-based Therapeutics*. Taylor & Francis: London, UK, 2002; pp. 33-53.
32. **Zhang R** and Wang H. Antisense Technology. In: D. T. Curiel and J.T. Douglas: *Contemporary Cancer Research: Cancer Gene Therapy*. Humana Press, Totowa, NJ, 2004; pp 35-49.
33. **Zhang R** and Wang H. Antisense Strategies for the Development of Novel Cancer Therapeutics. In: A.A. Adjei and J.K. Buolamwini, eds. *Strategies for Discovery and Clinical Testing of Novel Anticancer Agents* 2004 (in press).
34. Rayburn E, Wang W, **Zhang R**, and Wang H. Antisense Approach in Drug Discovery and Development In: *Advances in Targeted Approaches for Cancer Therapy*, Ed R.M. Schultz (in press)

## **PUBLISHED ABSTRACTS/PRESENTATIONS**

1. Jiang X, **Zhang R**, Gu X. Epidemiological study of the cancer mortality among employees exposed to formaldehyde in China. The XXII International Congress on Occupational Health, Sydney, Australia, Sept. 1987.
2. Jiang X, **Zhang R**, Gu X. Study of urinary formic acid as an index of biological monitoring of formaldehyde exposure. The XXII International Congress on Occupational Health, Sydney, Australia, Sept. 1987.
3. **Zhang R**, Jiang X. Pulmonary effects of chronic formaldehyde exposure. *Shanghai Occup Hlth* 1988; 3.
4. **Zhang R**, Jiang X. Epidemiological study of work-related diseases in employees exposed to formaldehyde. *Shanghai Occup Hlth* 1988; 2.
5. Jiang X, **Zhang R**. Cancer mortality among anatomists. *Shanghai Occup Hlth* 1988; 50.
6. **Zhang R**, Jiang X. Biological monitoring for formaldehyde exposure. *Shanghai Occup Hlth* 1988; 35.
7. **Zhang R**, Jiang X. Survival effects in epidemiological studies: cases and control. The 4th National Congress on Occupational Medicine and Industrial Toxicology, Tianjing, 1988.
8. **Zhang R**, Jiang X. Evaluation on occupational exposure limit for formaldehyde based on experimental and epidemiological studies. The 4th National Congress on Occupational Medicine and Industrial Toxicology, Tianjing, 1988.
9. Daher GC, Harris BE, **Zhang R**, Willard EM, Soong S-j, Diasio RB. The role of dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (dThdPase) in the

Curriculum Vitae

Ruiwen Zhang, M.D., Ph.D., D.A.B.T.

Page 32

circadian variation of plasma drug levels of 5-fluorouracil (FUra) and 5-fluoro-2'-deoxyuridine (FdUrd) following infusion of FUra and FdUrd. The Fourth International Conference of Chronopharmacology and Chronotherapeutics, Nice, March 12-15, 1990.

10. Daher GC, Nagib FNM, el Kouni MH, **Zhang R**, Diasio RB. Biochemical modulation of fluoropyrimidine catabolism Possible relevance to regional chemotherapy. *FASEB Journal* 1990; 4: A886.
11. Daher GC, **Zhang R**, Soon S-j, Diasio RB. Circadian variation of pyrimidine catabolizing enzymes in rat liver: possible relevance to 5-fluorodeoxyuridine (FdUrd) chemotherapy. *Proc Am Assoc Cancer Res* 1990; 31: 386.
12. **Zhang R**, Johnson MR, Barnes S, Diasio RB. Enterohepatic circulation (EHC) of 2-fluoro- $\beta$ -alanine conjugates of bile acids, the primary biliary metabolites of fluoropyrimidine. *Hepatology* 1990; 12(4): 897.
13. **Zhang R**, Barnes S, Diasio RB. Differential intestinal deconjugation of bile acid N-acyl amides: Basis for the high ratio of taurine to glycine-conjugated bile acid N-acyl amides in rat bile. *Gastroenterology* 1991; 100(5): A816.
14. **Zhang R**, Barnes S, Diasio RB. Pharmacokinetics and tissue distribution of 2-fluoro- $\beta$ -alanine, the major metabolite of fluoropyrimidine drugs. *Proc Am Assoc Cancer Res* 1991; 32: 345.
15. Lu Z, **Zhang R**, Diasio RB. Purification and characterization of dihydropyrimidine dehydrogenase from human liver. *Proc Am Assoc Cancer Res* 1992; 33: 11.
16. Diasio RB, **Zhang R**, Lu Z, Liu T, Soong S-j. Circadian variation of fluoropyrimidine metabolic enzymes: importance to 5-fluorodeoxyuridine (FdUrd) chemotherapy. *Biological Rhythms and Medications*, The 5th International Conference of Chronopharmacology and Chronotherapeutics, Amelia Island, Florida, July 12-16, 1992, pp.IV-1.
17. **Zhang R**, Lu Z, Liu T, Soong S-j, Diasio RB. Circadian rhythm of rat spleen cytoplasmic thymidine kinase: possible relevance to 5-fluorodeoxyuridine chemotherapy. *Biological Rhythms and Medications*, The 5th International Conference of Chronopharmacology and Chronotherapeutics, Amelia Island, Florida, July 12-16, 1992, pp.IV-3.
18. **Zhang R**, Lu Z, Diasio C, Liu T, Soong S-j, Diasio RB. Circadian rhythm of cytoplasmic thymidine kinase in rat bone marrow and intestinal mucosa: possible relevance to fluorodeoxyuridine (FdUrd) and 3'-azido-3'-deoxythymidine (AZT) chemotherapy. *FASEB J* 1993; 7 (4): A689.
19. Guttman R, **Zhang R**, Lu Z, Diasio RB. Biochemical evidence for bile acid amide deconjugating activity outside the intestinal contents in rats. *FASEB J* 1993; 7 (4): A702.
20. **Zhang R**, Lu Z, Guttman R, and Diasio RB. The time of administration of 3'-azido-3'-deoxythymidine (AZT) determines its toxicity. *Proc Am Assoc Cancer Res* 1993; 34: 280.

21. Lu Z, **Zhang R**, Diasio RB. Circadian dependent toxicity of fluorodeoxyuridine (FdUrd); Possibly related to circadian variation of thymidine kinase (TK) activity in bone marrow and intestinal mucosa. *Proc Am Assoc Cancer Res* 1993; 34: 413.
22. Lu Z, **Zhang R**, Diasio RB. Clinical implication of dihydropyrimidine dehydrogenase (DPD) assay in fluoropyrimidine (FP) chemotherapy. *Proc Am Soc Clin Oncol* 1993; 12:129.
23. Lu Z, **Zhang R**, Diasio RB. Genetic polymorphism of dihydropyrimidine dehydrogenase (DPD), the key enzyme in 5-fluorouracil (FUra) catabolism. *Clin Pharm Ther* 1994; 54: 180.
24. Cheng X, **Zhang R**, Lu Z, Falany C, Diasio RB. Molecular cloning of dihydropyrimidine dehydrogenase (DPD); Isolation of cDNA fragments of bovine liver DPD. *Clin Pharm Ther* 1994; 54: 188.
25. Lu Z, **Zhang R**, Carpenter J, Diasio RB. Frequency of dihydropyrimidine dehydrogenase (DPD) deficiency. *Proc Am Assoc Cancer Res* 1994; 35: 227.
26. **Zhang R**, Lu Z, Diasio RB. Quantitation of dihydropyrimidine dehydrogenase (DPD) using a polyclonal antibody to human liver DPD. *Proc Am Assoc Cancer Res* 1994; 35: 200.
27. Diasio RB, Lu Z, **Zhang R**, Cheng X. Genetic polymorphism of dihydropyrimidine dehydrogenase: implications for 5-fluorouracil metabolism and toxicity. *Proc Am Assoc Cancer Res* 1994; 35: 688.
28. Diasio RB, Kuilenburg V, Lu Z, **Zhang R**, Lenthe V, Bakker HD, Gennip V. Determination of dihydropyrimidine dehydrogenase (DPD) in fibroblasts of a DPD deficient pediatric patient and family members using a polyclonal antibody to human DPD. The Eighth International Symposium on Purine and Pyrimidine Metabolism (1994).
29. Carpenter J, Lu Z, **Zhang R**, Diasio RB. Role of dihydropyrimidine dehydrogenase (DPD) in chemotherapy with 5-fluorouracil. The Lancet Conference (1994).
30. Lu Z, **Zhang R**, Diasio RB. Dihydropyrimidine dehydrogenase (DPD) activity in cancer patients: Relevance to 5-fluorouracil (FUra) chemotherapy. *Proc Am Soc Clin Oncol* (1994).
31. Diasio RB, **Zhang R**, Lu Z. Circadian biochemical pharmacology in cancer chemotherapy with fluoropyrimidine antimetabolites. The Society for Research on Biological Rhythms International Conference of Chronobiology, Amelia Island, Florida, May 1994
32. **Zhang R**, Lu Z, Spector T, Diasio RB. Importance of dihydropyrimidine dehydrogenase in circadian-dependent toxicity of 5-fluorodeoxyuridine: Effects of 5- ethynyluracil, an

Curriculum Vitae

Ruiwen Zhang, M.D., Ph.D., D.A.B.T.

Page 34

inhibitor of DPD. Biological Rhythms and Medications. The 6th International Conference of Chronopharmacology and Chronotherapeutics, Amelia Island, Florida, 1994, pp. VIIa-3.

33. Diasio RB, **Zhang R.** Chronopharmacology of anticancer therapeutic agents in animals. International Symposium: Chronotherapy of Cancer from Experimental to Clinical Aspects. Liege, Belgium, Oct 1, 1994.

34. Diasio RB, **Zhang R.** Chronopharmacokinetics of anticancer therapeutic agents in humans International Symposium Chronotherapy of Cancer from Experimental to Clinical Aspects. Liege, Belgium, Oct 1, 1994.

35. **Zhang R**, Yan J, Shahinian H, Amin G, Lu Z, Saag MS, Jiang Z, Temsamani J, Schechter PJ, Martin RR, Agrawal S, Diasio RB. Human pharmacokinetics of an anti-HIV antisense oligonucleotide phosphorothioate (GEM 91) in HIV-infected individuals. The 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Orlando, FL, Oct 4-7, 1994. Later Breaker Session A5, pp. 5.

36. **Zhang R**, Lu Z, Zhang X, Diasio RB, Jiang Z, Agrawal S. In vivo biostability, pharmacokinetics, and disposition in rats of a "self-stabilized" antisense oligodeoxynucleotide phosphorothioate. *Genetic Revolution -- The 2nd San Diego Conference of American Association of Clinical Chemistry*, San Diego, CA, Nov. 16-19, 1994 (Abstract # 15)

37. **Zhang R**, Lu Z, Yan J, Diasio RB, Jiang Z, Temsamani J, Schechter PJ, Agrawal S. In vivo stability and pharmacokinetics of an anti-HIV antisense oligonucleotide phosphorothioate (GEM 91) in rats and HIV-infected individuals. The 2nd Conference on Human Retrovirus and Related Infections, Washington DC, Jan. 29-Feb. 2, 1995.

38. Zhang X, Lu Z, Diasio RB, Jiang Z, Tan W, Agrawal S, **Zhang R.** Plasma- and serum-protein binding of antisense oligodeoxynucleotide phosphorothioates in experimental animals and humans. *Proc Am Assoc Cancer Res* 1995; 36: 411.

39. Lu Z, Zhao H, Diasio RB, Habus I, Jiang Z, Tan W, Agrawal S, **Zhang R.** In vivo stability, pharmacokinetics, and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats. *Proc Am Assoc Cancer Res* 1995; 36:411.

40. Liu T-P, Lu Z, Diasio RB, Agrawal S, **Zhang R.** Mathematical modeling of biodistribution of an antisense oligodeoxynucleotide phosphorothioate. *Proc Am Assoc Cancer Res* 1995; 36: 364.

41. Khor SP, Lucos S, Schilsky R, Burris H, Von Hoff DD, **Zhang R**, Spector T. A phase I/pharmacokinetic study of 5-ethynyluracil plus 5-fluorouracil in cancer patients with solid tumors. *Proc Am Assoc Cancer Res* 1995; 36: 241.

42. Zhao H, Lu Z, Diasio RB, Agrawal S, **Zhang R.** Biliary excretion of oligonucleotides: Previously unrecognized pathway in metabolism of antisense oligonucleotides. Presented at

the FASEB Annual Meeting--Experimental Biology 95, Atlanta, GA, April 9-13, 1995.  
FASEB Journal 9 (3): A410.

43. **Zhang R**, Lu Z, Diasio RB, Agrawal S. Comparative pharmacokinetics of antisense oligonucleotide phosphorothioates and modified analogs. International Conference "Therapeutic Oligonucleotides From Cell To Man", Seillac, France, April 4-7, 1995.

44. Shahinian H, Amin G, Stewart M, Olsen S, Yan J, **Zhang R**, Diasio RB. Inhibition of peripheral blood mononuclear cell (PBMC) dihydropyrimidine dehydrogenase (DPD) activity by sorivudine [1-B-D-arabino-furranosyl-E-5-(2-bromovinyl)-uracil] and its role in severe fluorouracil (FUra) toxicity. *Pro Am Soc Clin Oncol* 1995; 14:169.

45. Amin G, Shahinian H, Miller D, Vukelj S, **Zhang R**, Lu Z, Diasio RB. Severe neurotoxicity following 5-fluorouracil (FUra) chemotherapy in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. *Pro Am Soc Clin Oncol* 1995; 14: 169.

46. Agrawal S, Diasio RB, **Zhang R**. Absorption, tissue distribution, and in vivo stability of "hybrid" oligonucleotide phosphorothioate following oral administration in rats. *Antisense Research and Development* 1995; 5: 161.

47. **Zhang R**, Lu Z, Agrawal S. Pharmacological evaluations of antisense oligonucleotides as gene expression modulators in the treatment of HIV infection. SCBA Sixth International Symposium, Vancouver, Canada, June 25-30, 1995 (Abstract # 129).

48. **Zhang R**, Lu Z, Iyer RP, Agrawal S. Pharmacokinetics and tissue distribution in rats of a chimeric oligodeoxynucleotide developed as an anti-HIV antisense agent. AAPS Annual Meeting, Miami, FL, November 5-9, 1995 (Abstract # 8132).

49. **Zhang R**, Zhang X, Gush KA, Kerr RG, Pettit GR, Kraft AS. Preclinical pharmacology of the natural product anticancer agent Bryostatin 1, an activator of protein kinase C. IBC Conference, Natural Products, Beijing, China, October 9-14, 1995.

50. Takimoto C, Lu Z, **Zhang R**, Liang M, Larson L, Grem JL, Allegra CL, Chu E. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. *Clin Pharm Ther* 1996; 59: 161.

51. Cai Q, Tian L, Chambless B, Li Y, Rahn RO, **Zhang R**. Inhibitory effects on oxidative DNA damage and lipid peroxidation, and the quenching of free radicals by the dietary components (luteolin, quercetin and genistein). *Proc Am Assoc Cancer Res* 1996; 37: 280.

52. Lu Z, **Zhang R**, Carpenter J, Yan J, Diasio RB. Decreased dihydropyrimidine dehydrogenase (DPD) activity in breast cancer patients; Potential increased risk for 5-fluorouracil toxicity. *Proc Am Assoc Cancer Res* 1996; 37: 184.

Curriculum Vitae

Ruiwen Zhang, M.D., Ph.D., D.A.B.T.

Page 36

53. Lu Z, Liu T, Habus I, Jiang Z, Agrawal S, **Zhang R**. Dose-dependent pharmacokinetics and metabolism of a hybrid oligonucleotide phosphorothioate in rats. *Proc Am Assoc Cancer Res* 1996; 37: 352.
54. Liu W, **Zhang R**. Upregulation of p21/WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by 10-hydroxycamptothecin (HCPT) and camptothecin (CPT) through p53-dependent and independent pathways. *Proc Am Assoc Cancer Res* 1997; 38: 15.
55. Cai Q, Lindsey JR, **Zhang R**. Regression of human colon cancer xenografts in SCID mice following oral administration of natural products, 10-hydroxycamptothecin (HCPT) and camptothecin (CPT). *Proc Am Assoc Cancer Res* 1997; 38: 309.
56. Xie X, Cai Q, Tan W, Agrawal S, **Zhang R**. Pharmacokinetics of a novel mixed-backbone oligonucleotide targeted at protein kinase A in SCID mice bearing human colon carcinoma xenografts. *Proc Am Assoc Cancer Res* 1997; 38: 317.
57. **Zhang R**, Cai Q, Li Y, Xu J, Xie X, Tan W, Agrawal S. Novel mixed-backbone oligonucleotides (MBO) targeted at protein kinase A with improved *in vivo* antitumor activities against human cancer xenografts. *Proc Am Assoc Cancer Res* 1997; 38: 316
58. Roland P, **Zhang R**, Li Y, Alvarez R. Human pharmacokinetics of sulindac as a chemopreventive agent. *Proc Am Assoc Cancer Res* 1997; 38: 597.
59. **Zhang R** and Agrawal S, Pharmacokinetics and bioavailability of oligonucleotides following oral and colorectal administrations in experimental animals. Antisense 97. Cambridge, MA, May 1-2, 1997. *Nature Biotech.* (Abstract # 88)
60. **Zhang R**, Li Y, Cai Q, Liu W, Xie X, Tan W, and Agrawal S, In vitro and *in vivo* antitumor activities of novel mixed-backbone oligonucleotides (MBO) targeted at protein kinase A (PKA). Antisense 97, Cambridge, MA, May 1-2, 1997. *Nature Biotech.* (Abstract # 87).
61. **Zhang R** and Agrawal S, Preclinical and clinical pharmacology of oligonucleotides as gene expression modulators. International Symposium on Gene Therapy, Beijing, July 7-10, 1997, *J Exp. Hematology* (Abstract #88).
62. **Zhang R**, Zeng XF and Agrawal S. Pharmacokinetics of new generations of antisense oligonucleotides. *Clin Pharm Ther* 1998, 63: 233.
63. **Zhang R**, Cai Q, Li Y and Chambless B. Enterohepatic circulation of natural product topoisomerase I inhibitors, camptothecin (CPT) and 10-hydroxycamptothecin (HCPT). *Clin Pharm Ther* 1998, 63: 219.

Curriculum Vitae

Ruiwen Zhang, M.D., Ph.D., D.A.B.T.

Page 37

64. Zeng XF, Agrawal S and **Zhang R**. Antitumor activities of novel antisense mixed-backbone oligonucleotides targeted at protein kinase A in nude mice bearing human cancer xenografts following oral administration. *Clin Pharm Ther* 1998; 63: 170.
65. Diasio RB, Lu Z and **Zhang R**. Decreased dihydropyrimidine dehydrogenase activity in breast cancer. *Clin Pharm Ther* 1998; 63: 171.
66. Zeng XF and **Zhang R**. Sulindac and its metabolites sulindac sulfide and sulindac sulfone induce apoptosis in human cervical cancer cells. *Pro Am Assc Cancer Res* 1998; 39: 196.
67. **Zhang R**, Zeng XF, Bowman JD and Agrawal S. Growth inhibition of human lung cancer A549 xenografts in nude mice following oral administration of mixed-backbone oligonucleotides targeted at protein kinase A. *Pro Am Assc Cancer Res* 1998; 39: 518.
68. Smith MJ, Spencer SA, **Zhang R**, and Robert F. Phase I/IIa study of sequential ifosfamide and topotecan in patients with small cell lung cancer. Selected for presentation at ASCO 1998 Annual Meeting, May 1998.
69. **Zhang R**. Antisense Oligonucleotide Therapeutics: Promises and Pitfalls. Presentation at the 6th Pacific Rim Biotechnology Conference and Bioexpo 98, June 1998.
70. **Zhang R**, Chen J and Agrawal S. Inhibiting mdm2 expression as a new approach to human cancer therapy. The first NCI annual meeting on the experimental therapeutics of human cancer, Frederic MD, June 11-13, 1998.
71. **Zhang R**, Chen J and Agrawal S. MDM2 as a drug target for cancer therapy. Selected for presentation at the 3rd World Conference on Oncology, Grece, Oct. 15-17, 1998. *Intl J Molecular Medicine* 2(S1):S10, 1998
72. **Zhang R**, Robert F, Shuey S, Dallaire BK. Pharmacokinetics of 9-aminocamptothecin (9-AC) in patients with solid tumors. Presentation at the Ninth Conference on DNA Topoisomerase in Therapy, NY Oct 5-7, 1998.
73. Robert F, **Zhang R**, Shuey S, Dallaire BK. Phase I clinical trial of 9-aminocamptothecin (9-AC) in patients with solid tumors by a daily times five schedule. Presentation at the Ninth Conference on DNA Topoisomerase in Therapy, NY Oct 5-7, 1998.
74. Platzer P, Thalhammer T, herzog W, Hamilton G, **Zhang R**, Jager W. In vitro metabolism of 10-hydroxylcamptothecin by rat and human liver microsomes. *Anticancer Res*. 1998; 18: 4930.
75. Roland PY, **Zhang R**, Li Y, Barnes M, Kilgore LC, Partridge EE, Alvarez RD. The Chemopreventive agent sulindac modulates prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) levels in cervical and vaginal secretions. The 29th Annual Meeting of the Society of Gynecologic Oncologists, 1998 (Abstract #128).

76. Chen L, Lu W, Agrawal S, **Zhang R**, Chen J. Induction of p53 in tumor cells by inhibition of mdm2 expression. Poster Presentations at the 9th International p53 Workshop, Wistar Institute, 1998
77. **Zhang R**, Wang H, Bale J, Robert F, Shuey S, Dallaire BK. Clinical pharmacokinetics (PK) of 9-aminocamptothecin (9-AC) following daily times five administration in patients with solid tumors. *Pro Am Assc Cancer Res* 1999; 40: 81.
78. **Zhang R**, Zeng XF, Oliver P, Chen J, Agrawal S. Inhibiting MDM2 oncogene expression as a new approach to cancer therapy. *Pro Am Assc Cancer Res* 1999; 40: 484.
79. Posey J, Delgrosso A, Saleh M, **Zhang R**, Robert F. A phase I dose escalation and sequencing study of taxotere and continuous infusion topotecan in patients with advanced malignancies. *Pro Am Soc Clin Oncol* 1999; 18: 224a
80. Robert F, **Zhang R**, Kimbrough T, Dallaire B, Shuey S. A phase I trial of 9-aminocamptothecin (9-AC), given on a daily X 5 intravenous (IV) bolus schedule in patients with solid tumors. *Pro Am Soc Clin Oncol* 1999; 18: 226a
81. Wang H, Agrawal S, **Zhang R**. Inhibiting MDM2 oncogene expression as a novel approach to human cancer therapy. Presented at the ASCPT Annual Meeting, Los Angles, CA, 2000.
82. Wang H, Agrawal S, **Zhang R**. Antitumor activities of a novel anti-MDM2 antisense oligonucleotide: p53-dependent and p53-independent mechanisms. Presented at the AACR Annual Meeting, San Francisco, CA, 2000.
83. Wang H, Agrawal S, **Zhang R**. Antitumor activities of a novel anti-PKA antisense oligonucleotide after oral administration. Presented at the Millennium Conference on Nucleic Acid Therapeutics, Clearwater Beach, FL, 2000.
84. **Zhang R**, Wang H, Agrawal S, Anti-MDM2 antisense oligonucleotide is an enhancer of cancer chemotherapy and radiation therapy. Presented at the Millennium Conference on Nucleic Acid Therapeutics, Clearwater Beach, FL, 2000.
85. Jager W, Platzer P, Thalhammer T, Hamilton G, **Zhang R**. Role of human liver microsomal CYP3A4 and UGT1A1 in the metabolism of the novel topoisomerase I inhibitor 10-hydroxycamptothecin. Presented at AAPS annual meeting, 2000.
86. Wang H, **Zhang R**. Antisense oligonucleotide therapeutics as a newl approach to breast cancer therapy: *in vitro* and *in vivo* studies. Presented at the 23rd Annual San Antonio Breast Cancer Symposium, 2000.
87. **Zhang R**, Wang H. Protein kinase A as a target for human cancer therapy. The 5th World Congress on Advances in Oncology, Crete, Greece, 2000.

88. Wang H, **Zhang R**. Antisense anti-MDM2 oligonucleotide therapeutics as a new approach to human cancer therapy: in vitro and in vivo studies. Presented at the 5th International Symposium on Predictive Oncology and Therapy Geneva, Switzerland, 2000.
89. **Zhang R**, Wang H. Novel center-modified antisense oligonucleotides: therapeutic efficacy, pharmacology, and toxicology. Presented at the 5th International Symposium on Predictive Oncology and Therapy Geneva, Switzerland, 2000.
90. Wang H, Wang S, Liang P, Prasad G, Nan L, Agrawal S, **Zhang R**. Improving chemotherapeutic effectiveness of irinotecan by antisense oligonucleotides. Presented at the AACR Annual Meeting, New Orleans, LA, 2001.
91. Wang H, Wang S, Wang Z, Oliver P, Nan L, Rhie J, **Zhang R**, Hill D. Tissue distribution of radiolabeled FAU (NSC 678515) and FMAU (NSC 678516) in tumor-bearing mice. Presented at the AACR Annual Meeting, New Orleans, LA, 2001.
92. Prasad G, Wang H, Nan L, Agrawal S, **Zhang R**. Inhibiting MDM2 oncogene expression as a novel approach to the treatment of glioblastoma multiforme. Presented at the AACR Annual Meeting, New Orleans, LA, 2001.
93. Wang H, **Zhang R**. Inhibiting MDM2 expression as a novel approach to human cancer therapy. In vitro and in vivo studies. Presented at the AACR Conference: *Molecular Biology and New Therapeutic Strategies*, Maui, Hawaii, 2001.
94. **Zhang R**, Wang H. Protein kinase A as a target for human cancer therapy. The 5<sup>th</sup> joint AACR/JCA conference, entitled *Molecular Biology and New Therapeutic Strategies: Cancer Research in the 21<sup>st</sup> Century*, Maui, Hawaii, Feb 12-16, 2001.
95. Wang H, Wang S, Wang Z, Li M, Nan L, **Zhang R**, Hill D. Pre-clinical in vitro and in vivo studies with Epothilone D, a novel tubulin stabilizing anti-cancer agent. Submitted to AACR-NCI-EORTC International Conference: *Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications*, Miami Beach, FL, Oct 29-Nov 2, 2001.
96. Wang H, Nan L, Agrawal S, **Zhang R**. Modulation of gene expression and inhibition of tumor growth by antisense anti-MDM2 oligonucleotides in prostate cancer. Submitted to AACR-NCI-EORTC International Conference: *Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications*, Miami Beach, FL, Oct 29-Nov 2, 2001.
97. Wang H, Hang J, Li M, Shi Z, Lin L, Kandimalla E, Yu D, Zhao Q, Agrawal S, **Zhang R**. Synthetic immunostimulatory oligonucleotides show anti-tumor activity and increase therapeutic effectiveness of monoclonal antibody and chemotherapeutic agents. Presented at the AACR 93<sup>rd</sup> Annual Meeting, San Francisco, CA, April 6-10, 2002.
98. Wang H, Yu D, Agrawal S, **Zhang R**. Antisense mixed-backbone oligonucleotides targeting cAMP-dependent protein kinase (PKA) enhance therapeutic efficacy of

topoisomerase I inhibitor irinotecan in nude mice bearing human Cancer xenografts: in vivo activity and mechanisms. Presented at the AACR 93<sup>rd</sup> Annual Meeting, San Francisco, CA, April 6-10, 2002.

99. Wang H, Dubuisson J, Huang P, Kandimalla ER, Yu D, Agrawal S, **Zhang R**. Novel synthetic immune stimulating oligonucleotides (IMO): Anti-tumor activity, Chemosensitization, and Pharmacokinetics. *Proc. 94<sup>th</sup> Annual Meeting AACR* 2003; Vol. 44, pp. 647-648 (abstract # 2838).
100. Wang H, Li M, Dubuisson J, Scachinger V, Haslinger M, Rinehart JJ, **Zhang R**. Dexamethasone as a chemoprotectant in cancer chemotherapy: Hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine. *Proc. 94<sup>th</sup> Annual Meeting AACR* 2003; Vol. 44, pp. 392 (abstract # 1729).
101. Wang H, Li M, Rinehart JJ, **Zhang R**. Dexamethasone increases anti-tumor activity and alters pharmacokinetics of carboplatin and gemcitabine *in vivo*. *Proc. 94<sup>th</sup> Annual Meeting AACR* 2003; Vol. 44, pp. 140 (abstract # 609).
102. Zhang Z, Wang H, Prasad G, Li M, Oliver P, Bonner J, Agrawal S, **Zhang R**. Radiosensitization of human cancers by inhibiting MDM2 expression: *In vitro* and *in vivo* models and mechanisms. *Proc. 94<sup>th</sup> Annual Meeting AACR* 2003; Vol. 44, pp. 1021 (abstract # 4460).
103. Zhang Z, Li M, Wang H, Yu D, Agrawal S, **Zhang R**. In vitro and *in vivo* antisense inhibiting MDM2 expression in prostate cancer models: Anti-proliferation, inducing apoptosis, modulating gene expression, and improving chemotherapy. *Proc. 94<sup>th</sup> Annual Meeting AACR* 2003; Vol. 44, pp. 1476 (abstract # 6439).
104. Wang H, Li M, Shi Z, Hang J, Rhie JK, Covey JM, **Zhang R**, Hill DL. Preclinical studies of 2-methoxyantimycin A3 (OME-A3), A novel antitumor agent and its analogs, OME-A1, OME-A2, and A5. *Proc. 94<sup>th</sup> Annual Meeting AACR* 2003; Vol. 44, pp. 1064 (abstract # 4638).
105. Kandimalla ER, Yu D, Bhagat L, Tang J, Wang H, **Zhang R**, Agrawal S. Immunomodulatory Oligonucleotides Containing CpG and Synthetic YpG, CpR, and YpR Motifs Induce Strong Innate Immune and Mediate Potent Antitumor Activity in Nude Mice Bearing Tumor Xenografts. *Proc. 94<sup>th</sup> Annual Meeting AACR* 2003; Vol. 44, pp. 1481 (abstract # 6462).
106. Goel S, Cho-Chung YS, Bulgaru A, Desai K, Wang H, Li M, McKinlay M, Martin R, **Zhang R**, Mani S. Extracellular PKA (ECPKA) activity in cancer patients treated with multiday continuous intravenous infusions (CIV) of GEM®231, a second-generation antisense oligonucleotide targeting PKA R1α subunit. *Proc. 94<sup>th</sup> Annual Meeting AACR* 2003; Vol. 44, pp. 150 (abstract # 653).
107. Lockhart AC, Rudin C, Berlin JD, Roth BJ, Hande KR, Martin RR, Sullivan TM, Grindel JM, **Zhang R**, Rothenberg ML. GEM®231, a second -generation anti-PKA

Curriculum Vitae

Ruiwen Zhang, M.D., Ph.D., D.A.B.T.

Page 41

oligonucleotide, administered with weekly CPT-11; A phase I trial. Submitted for presentation at the ASCO 2003 Annual Meeting, Chicago, IL

108. Wang H, Li M, Schachner V, Haslinger M, Agrawal, S, **Zhang R**. Antisense anti-cAMP-dependent protein kinase (PKA) oligonucleotide (GEM®231) enhances therapeutic effectiveness of topoisomerase I inhibitor irinotecan: preclinical models and pharmacokinetics. Submitted for presentation at the ASCO 2003 Annual Meeting, Chicago, IL.
109. Wang H, Li M, Covey JM, Stinson S, Velez K, Grossi I, Peggins J, Hill DL, **Zhang R**. Stability, plasma protein binding, and preclinical pharmacokinetics of adaphostin (NSC 680410), a tyrophostin analog that inhibits bcr/abl. Presented at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference, Boston, MA. Nov.17-21, 2003.
110. Wang H, Huang P, Kandimalla ER, Yu D, Agrawal S, **Zhang R**. Preclinical antitumor evaluation of a second-generation immunomodulatory oligonucleotide (IMO), HYB2055, alone and in combination with taxotere and gemcitabine. Presented at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference, Boston, MA. Nov.17-21, 2003.
111. LaCasse E, McManus D, Cherton-Horvat G, Wang H, Kandimalla ER, **Zhang R**, Agrawal S, Batist G, Kandouz M, Vanderhyden B, Shaw T, Durkin J. The XIAP Antisense Compound, AEG35156/GEM640, Exhibits Profound Antitumor Activity in Multiple Human Cancer Xenograft Models. Presented at the AACR and Japanese Cancer association Conference: *Advances in Cancer Research*. Waikoloa, Hawaii, Jan 25-29, 2004.
112. Li M, Zhang Z, Wang H, **Zhang R**. Genistein inhibits MDM2 expression independent of p53, a previously unrecognized mechanism of action. Presented at the 2004 AACR annual meeting, Orlando, FL, March 27-31, 2004
113. Zhang Z, Li M, Wang H, Agrawal S, Chen X, **Zhang R**. MDM2 is a direct, p53-independent, negative regulator of p21. Presented at the 2004 AACR annual meeting, Orlando, FL, March 27-31, 2004
114. Sun M, Zhang Z, Prasad G, Wang Y, Agrawal S, **Zhang R**, Wang H. The role of p53 and p21 in cancer therapy with MDM2 inhibitor. Presented at the 2004 AACR annual meeting, Orlando, FL, March 27-31, 2004.
115. Wang H, Li M, Covey JM, **Zhang R**, Hill DL. Preclinical studies with dihydronaphthalene monophenol (NSC D725087), a vascular targeting agent, and its monophosphate prodrug (NSC D725088). Presented at the 2004 AACR annual meeting, Orlando, FL, March 27-31, 2004.
116. Wang H, Rayburn E, Zhang Z, Wang Y, Li M, Kandimalla ER, Yu D, Agrawal S, **Zhang R**. A second-generation immunomodulatory oligonucleotide agonist of TLR9 shows antitumor activity and enhances effects of chemotherapy, radiation and antibody therapy in vitro and in vivo. Selected for presentation at the 2005 AACR annual meeting, Anaheim, CA, April 16-20, 2005.

**Curriculum Vitae**

**Ruiwen Zhang, M.D., Ph.D., D.A.B.T.**

Page 42

117. Li M, Zhang Z, Rayburn E, Wang H, He T-C, **Zhang R.** Antitumor activity and chemosensitization effects of novel antisense oligonucleotides targeting beta-catenin. Presented at the 2005 AACR annual meeting, Anaheim, CA, April 16-20, 2005.
118. Wang H, Li M, Wang Y, Kandimalla ER, Yu D, Agrawal S, **Zhang R.** In vivo antitumor activity and chemosensitization effects of novel antisense oligonucleotides targeting VEGF. Presented at the 2005 AACR annual meeting, Anaheim, CA, April 16-20, 2005.
119. Li M, Wang H, Wang W, Grossi IM, Tosa PJ, Peggins JO, Xing HR, Kolesnick RN, Covey J, Hill DL, **Zhang R.** Preclinical studies with an Antisense Phosphorothioate Oligodeoxynucleotide (KSR AS-214231; NSC 731442), an Inhibitor of Ras Signaling. Presented at the 2005 AACR annual meeting, Anaheim, CA, April 16-20, 2005.
120. Zhang Z, Li M, Wang H, Chen, Agrawal S, **Zhang R.** Stabilization of E2F1 protein contributing to the p53-independent activities of MDM2. Presented at the 2005 AACR annual meeting, Anaheim, CA, April 16-20, 2005.

## **MISCELLANEOUS/Course Developed Modern Drug Design and Development (PHR725)**

**Course Director:**

**Ruiwen Zhang, MD, PhD, DABT**

**Credit Hours:**

**3**

**Students:**

PhD students in Pharmacology, Toxicology, Microbiology, Chemistry, and other life sciences (2<sup>nd</sup> year and above)

**Learning Objectives:**

Understanding principles and practice of drug discovery, evaluation and development.

**Major Lectures:**

- Introduction to MDDD
- The Evolving Drug Discovery and Development Process
- Drug Approval Procedure and Regulatory Issues
- Rational Drug Design I: Target Discovery
- Rational Drug Design II: Target Validation
- Rational Drug Design III: Computer-Aided Drug Design
- Rational Drug Design IV: Combinatorial Chemistry and High-Volume Screening
- Rational Drug Design V: Biotechnology
- Rational Drug Design VI: Novel Drug Delivery System
- Rational Drug Design VII: Structure Biology
- Rational Drug Design VIII: Genomics/Proteomics
- Pre-clinical Evaluation of Drugs
- Disease Models
- Pharmacokinetics and Pharmacodynamics
- *In vitro* and *in vivo* Toxicology
- GLP/GMP/GCP
- Clinical Pharmacology in Drug Development
- Pharmacogenetics/Pharmacogenomics
- Clinical Trials
- Contract research
- Intellectual properties protection